WO2002043785A2 - Intraocular implants for preventing transplant rejection in the eye - Google Patents

Intraocular implants for preventing transplant rejection in the eye Download PDF

Info

Publication number
WO2002043785A2
WO2002043785A2 PCT/US2001/044481 US0144481W WO0243785A2 WO 2002043785 A2 WO2002043785 A2 WO 2002043785A2 US 0144481 W US0144481 W US 0144481W WO 0243785 A2 WO0243785 A2 WO 0243785A2
Authority
WO
WIPO (PCT)
Prior art keywords
bioerodible
drug delivery
delivery system
eye
weight
Prior art date
Application number
PCT/US2001/044481
Other languages
French (fr)
Other versions
WO2002043785A3 (en
Inventor
Vernon G. Wong
Original Assignee
Oculex Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oculex Pharmaceuticals, Inc. filed Critical Oculex Pharmaceuticals, Inc.
Priority to DE60114229T priority Critical patent/DE60114229T2/en
Priority to BR0115772-8A priority patent/BR0115772A/en
Priority to AU2002236495A priority patent/AU2002236495B2/en
Priority to AU3649502A priority patent/AU3649502A/en
Priority to JP2002545755A priority patent/JP2004514702A/en
Priority to CA2429998A priority patent/CA2429998C/en
Priority to EP01986027A priority patent/EP1339438B1/en
Priority to AT01986027T priority patent/ATE306951T1/en
Publication of WO2002043785A2 publication Critical patent/WO2002043785A2/en
Publication of WO2002043785A3 publication Critical patent/WO2002043785A3/en
Priority to AU2006201271A priority patent/AU2006201271B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008Introducing ophthalmic products into the ocular cavity or retaining products therein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/22Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
    • A61L2300/222Steroids, e.g. corticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41Anti-inflammatory agents, e.g. NSAIDs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602Type of release, e.g. controlled, sustained, slow
    • A61L2300/604Biodegradation

Definitions

  • This invention relates to the field of transplantation, in particular transplantation of components of the eye, and methods for preventing transplant rejection.
  • Certain conditions and diseases of the eye such as corneal failure, keratoconus, corneal dystrophies, scarring, age related macular degeneration (AMD) and retinitis pigmentosa, have been treated using ocular transplant procedures such as corneal and retinal pigment epithelial (RPE) transplants.
  • Transplant rejection is one of the problems which may arise from transplant procedures (Enzmann V et al. (1998).
  • One embodiment of the present invention provides a method for reducing or preventing transplant rejection in the eye of an individual, where the method comprises: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
  • Another embodiment of the invention provides a method for reducing or preventing transplant rejection in the eye of an individual, where the method comprises: a) performing an ocular transplant procedure; and b) implanting a solid body into the eye, said body comprising particles of an immunosuppressive agent entrapped within a bioerodible polymer, whereby said agent is released from the body by erosion of the polymer.
  • Another embodiment of the invention provides a method which includes placing in an eye of an individual a bioerodible drug delivery system, where the bioerodible drug delivery system includes an immunosuppressive agent and a bioerodible polymer; and where the eye of the individual has undergone or is undergoing an ocular transplant procedure. This method may be used to reduce or prevent transplant rejection.
  • Another embodiment of the invention provides a kit comprising: a) a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer, wherein the drug delivery system is designed to be implanted in the eye; and b) instructions for use. This kit may be used to reduce or prevent transplant rejection.
  • ocular transplant procedure refers to any transplant procedure performed in the eye.
  • Non-limiting examples of ocular transplant procedures include, but are not limited to, retinal pigment epithelium (RPE) transplant and cornea transplant. It includes autograft, allograft and xenograft transplant procedures.
  • RPE retinal pigment epithelium
  • Immunosuppressive agent "agent”
  • Immunosuppressive drug and
  • drug are used interchangeably herein, and refer to any agent which inhibits or prevents an immune response against the transplanted tissue following a transplant procedure.
  • exemplary agents include, but are not limited to, dexamethasone, cyclosporin A, azathioprine, brequinar, gusperimus, 6-mercaptopurine, mizoribine, rapamycin, tacrolimus
  • folic acid analogs e.g., denopterin, edatrexate, methotrexate, piritrexim, pteropterin, Tomudex®, trimetrexate
  • purine analogs e.g., cladribine, fludarabine, 6- mercaptopurine, thiamiprine, thiaguanine
  • pyrimidine analogs e.g., ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, doxifluridine, emitefur, enocitabine, floxuridine, fluorouracil, gemcitabine, tegafur
  • fluocinolone triaminolone, anecortave acetate, flurometholone, medrysone, and prednislone.
  • an “implant” and a “drug delivery system,” are used interchangeably herein, and include any bioerodible device for implantation in the eye which is capable of delivering a therapeutic level of drug to the eye.
  • terapéutica level is meant a level of drug sufficient to prevent, inhibit, or reduce the level of transplant rejection in the eye.
  • bioerodible polymer refers to polymers which degrade in vivo, and wherein erosion of the polymer over time is required to achieve the agent release kinetics according to the invention.
  • hydrogels such as methylcellulose which act to release drug through polymer swelling are specifically excluded from the term
  • bioerodible polymer The terms “bioerodible” and “biodegradable” are equivalent and are used interchangeably in this patent.
  • mammals include, but are not limited to, humans, rodents, sport animals and pets, such as rats, dogs, and horses.
  • Intraocular immunosuppressive drug delivery systems made of a biodegradable polymer matrix are provided which can release drug loads over various programmed time periods. When inserted into the eye these drug delivery systems provide therapeutic levels of immunosuppressive agent for reducing or preventing transplant rejection.
  • one embodiment of the present invention provides a method for reducing or preventing transplant rejection in the eye of an individual, comprising: performing an ocular transplant procedure; and implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
  • a method for reducing or preventing transplant rejection in the eye of an individual comprising: performing an ocular transplant procedure; and implanting a solid body into the eye, said body comprising particles of an immunosuppressive agent entrapped within a bioerodible polymer, whereby said agent is released from the body by erosion of the polymer.
  • Ocular transplant procedures which may be used with the methods of the invention include, but are not limited to, cornea transplant and RPE transplant. Methods for performing these transplant procedures are well known in the art. Methods for performing RPE transplants are described in, for example, U.S. Pat. Nos. 5,962,027, 6,045,791 , and 5,941 ,250 and in Eye Graefes Arch Clin Exp Opthalmol 1997 Mar; 235(3): 149-58; Biochem Biophys Res Commun 2000 Feb 24; 268(3): 842-6; Opthalmic Surg 1991 Feb; 22(2): 102-8. Methods for performing corneal transplants are described in, for example, U.S. Pat. No.
  • the ocular transplant procedure is a cornea transplant.
  • the ocular transplant procedure is an RPE procedure.
  • the drug delivery system may be implanted at various sites in the eye, depending on the size, shape and formulation of the implant, the type of transplant procedure, etc. Suitable sites include but are not limited to the anterior chamber, anterior segment, posterior chamber, posterior segment, vitreous cavity, suprachoroidal space, subconjunctiva, episcleral, intracomeal, epicorneal and sclera.
  • the drug delivery system is placed in the anterior chamber of the eye.
  • the drug delivery system is placed in the vitreous cavity.
  • the implants may be inserted into the eye by a variety of methods, including placement by forceps or by trocar following making an incision in the sclera (for example, a 2-3 mm incision) or other suitable site.
  • the implant may be able to be placed by trocar without making a separate incision, but instead by punching a hole directly into the eye with the trocar.
  • the method of placement may influence the drug release kinetics. For example, implanting the device into the vitreous with a trocar may result in placement of the device deeper within the vitreous than placement by forceps, which may result in the implant being closer to the edge of the vitreous.
  • the location of the implanted device may influence the concentration gradients of drug surrounding the device, and thus influence the release rates (e.g., a device placed closer to the edge of the vitreous may result in a slower release rate).
  • U.S. Pat. No. 5,869,079 further describes locations for intraocular implants and methods for insertion (see in particular col. 6-7).
  • the implant delivers the immunosuppressive agent for at least about 5 days. In other embodiments, the implant delivers the immunosuppressive agent for at least about one week, at least about 2 weeks, at least about 3 weeks, at least about four weeks, at least about five weeks, at least about six weeks, at least about seven weeks, at least about eight weeks, at least about nine weeks, at least about 10 weeks, and at least about 12 weeks.
  • the preferred duration of drug release may be determined by the type of transplant, the medical history of the patient, etc. In one embodiment, drug release may occur for up to 6 months, or one year, or longer. In one embodiment, more than one implant may be sequentially implanted into the vitreous in order to maintain drug concentrations for even longer periods.
  • more than one implant may be sequentially implanted into the eye in order to maintain therapeutic drug concentrations for longer periods.
  • the methods of the invention are preferably performed on vertebrates, preferably mammal, more preferably a human. Mammals include, but are not limited to, humans, rodents, sport animals and pets, such as rats, dogs and horses.
  • the formulation of the implants for use in the invention may vary according to the preferred drug release profile, the particular immunosuppressive agent used, the transplant procedure, the medical history of the patient and other factors affecting the formulation.
  • the implants of the invention are formulated with particles of the immunosuppressive agent associated with the bioerodible polymer matrix.
  • the immunosuppressive agent is entrapped within the bioerodible polymer matrix.
  • release of the agent is achieved by erosion of the polymer followed by exposure of previously entrapped agent particles to the eye, and subsequent dissolution and release of agent.
  • the release kinetics achieved by this form of drug release are different than that achieved through formulations which release drug through polymer swelling, such as with hydrogels such as methylcellulose. In that case, the drug is not released through polymer erosion, but through polymer swelling, which release drug as liquid diffuses through the pathways exposed.
  • the parameters which may determine the release kinetics include the size of the drug particles, the water solubility of the drug, the ratio of drug to polymer, the method of manufacture, the surface area exposed, and the erosion rate of the polymer.
  • the immunosuppressive agent is selected from the group consisting of dexamethasone, cyclosporin A, azathioprine, brequinar, gusperimus, 6-mercaptopurine, mizoribine, rapamycin, tacrolimus (FK-506), folic acid analogs (e.g., denopterin, edatrexate, methotrexate, piritrexim, pteropterin, Tomudex®, trimetrexate), purine analogs (e.g., cladribine, fludarabine, 6-mercaptopurine, thiamiprine, thiaguanine), pyrimidine analogs (e.g., ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, doxifluridine, emitefur, enocitabine, floxuridine, fluorouracil, gemcitabine, tegafur) fluo
  • the immunosuppressive agent is cyclosporin A.
  • the bioerodible implant comprises more than one immunosuppressive agent.
  • the implants may further comprise one or more additional therapeutic agents, such as antibiotics or antiinflammatory agents.
  • additional therapeutic agents such as antibiotics or antiinflammatory agents.
  • antibiotics include, but are not limited to:
  • Aminoglycosides e.g., amikacin, apramycin, arbekacin, bambermycins, butirosin, dibekacin, dihydrostreptomycin, fortimicin(s), gentamicin, isepamicin, kanamycin, micronomicin, neomycin, neomycin undecylenate, netilmicin, paromomycin, ribostamycin, sisomicin, spectinomycin, streptomycin, tobramycin, trospectomycin), amphenicols (e.g., azidamfenicol, chloramphenicol, florfenicol, thiamphenicol), ansamycins (e.g., rifamide, rifampin, rifamycin sv, rifapentine, rifaximin), ⁇ -lactams (e.g., carbacephems (e.g.
  • 2,4-Diaminopyrimidines e.g., brodimoprim, tetroxoprim, trimethoprim
  • nitrofurans e.g., furaltadone, furazolium chloride, nifuradene, nifuratel, nifurfoline, nifurpirinol, nifurprazine, nifurtoinol, nitrofurantoin
  • quinolones and analogs e.g., cinoxacin, ciprofloxacin, clinafloxacin, difloxacin, enoxacin, fleroxacin, flumequine, grepafloxacin, lomefloxacin, miloxacin, nadifloxacin, nalidixic acid, norfloxacin, ofloxacin, oxolinic acid, pazufloxacin, pefloxacin, pipemidic acid, piromidic
  • Polyenes e.g. , amphotericin b, candicidin, dermostatin, filipin, fungichromin, hachimycin, hamycin, lucensomycin, mepartricin, natamycin, nystatin, pecilocin, perimycin
  • others e.g., azaserine, griseofulvin, oligomycins, neomycin undecylenate, pyrrolnitrin, siccanin, tubercidin, viridin.
  • Allylamines e.g. , butenafine, naftifine, terbinafine
  • imidazoles e.g. , bifonazole, butoconazole, chlordantoin, chlormidazole, cloconazole, clotrimazole, econazole, enilconazole, fenticonazole, flutrimazole, isoconazole, ketoconazole, lanoconazole, miconazole, omoconazole, oxiconazole nitrate, sertaconazole, sulconazole, tioconazole), thiocarbamates (e.g., tolciclate, tolindate, tolnaftate), triazoles (e.g., fluconazole, itraconazole, saperconazole, terconazole) others (e.g., acrisorcin, amorolfine, biphenamine,
  • Antibiotics and analogs e.g., aclacinomycins, actinomycin f l5 anthramycin, azaserine, bleomycins, cactinomycin, carubicin, carzinophilin, chromomycins, dactinomycin, daunorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, idarubicin, menogaril, mitomycins, mycophenolic acid, nogalamycin, olivomycines, peplomycin, pirarubicin, plicamycin, porfiromycin, puromycin, streptonigrin, streptozocin, tubercidin, zinostatin, zorubicin), antimetabolites (e.g., aclacinomycins, actinomycin f l5 anthramycin, azaserine, bleomycins, cactinomycin
  • folic acid analogs e.g., denopterin, edatrexate, methotrexate, piritrexim, pteropterin, Tomudex ® , trimetrexate
  • purine analogs e.g., cladribine, fludarabine, 6-mercaptopurine, thiamiprine, thioguanine
  • pyrimidine analogs e.g., ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, doxifluridine, emitefur, enocitabine, floxuridine, fluorouracil, gemcitabine, tagafur.
  • Specific antiinflammatory agents include, but are not limited to: Steroidal antiinflammatory agents:
  • Non-steroidal antiinflammatory agents are non-steroidal antiinflammatory agents.
  • Aminoarylcarboxylic acid derivatives e.g., enfenamic acid, etofenamate, flufenamic acid, isonixin, meclofenamic acid, mefenamic acid, niflumic acid, talniflumate, terofenamate, tolfenamic acid
  • arylacetic acid derivatives e.g., aceclofenac, acemetacin, alclofenac, amfenac, amtolmetin guacil, bromfenac, bufexamac, cinmetacin, clopirac, diclofenac sodium, etodolac, felbinac, fenclozic acid, fentiazac, glucametacin, ibufenac, indomethacin, isofezolac, isoxepac, lonazolac, metiazinic acid, mofezolac, ox
  • arylpropionic acid derivatives e.g., alminoprofen, benoxaprofen, bermoprofen, bucloxic acid, carprofen, fenoprofen, flunoxaprofen, flurbiprofen, ibuprofen, ibuproxam, indoprofen, ketoprofen, loxoprofen, naproxen, oxaprozin, piketoprolen, pirprofen, pranoprofen, protizinic acid, suprofen, tiaprofenic acid, ximoprofen, zaltoprofen), pyrazoles (e.g., difenamizole, epirizole), pyrazolones (e.g., apazone, benzpiperylon, feprazone, mofebutazone, morazone,
  • 3-amino-4-hydroxybutyric acid amixetrine, bendazac, benzydamine, ⁇ -bisabolol, bucolome, difenpiramide, ditazol, emorfazone, fepradinol, guaiazulene, nabumetone, nimesulide, oxaceprol, paranyline, perisoxal, proquazone, superoxide dismutase, tenidap, and zileuton.
  • the immunosuppressive agent is preferably from about 10 to 90% by weight of the implant. More preferably, the agent is from about 50 to about 80% by weight of the implant. In a preferred embodiment, the agent comprises about 50% by weight of the implant. In a preferred embodiment, the agent comprises about 70% by weight of the implant.
  • the implants are preferably monolithic, i.e. having the immunosuppressive agent homogeneously distributed through the polymeric matrix.
  • immunosuppressive agent is distributed evenly enough that no detrimental fluctuations in rate of immunosuppressive agent release occur because of uneven distribution of the immunosuppressive agent in the polymer matrix.
  • the selection of the polymeric composition to be employed will vary with the desired release kinetics, the location of the implant, patient tolerance, the nature of the transplant procedure and the like. Characteristics of the polymers will include biodegradabihty at the site of implantation, compatibility with the agent of interest, ease of encapsulation, water insolubility, and the like.
  • the polymeric matrix will not be fully degraded until the drug load has been released.
  • the polymer will usually comprise at least about 10, more usually at least about 20 weight percent of the implant.
  • the implant comprises more than one polymer.
  • Biodegradable polymeric compositions which may be employed may be organic esters or ethers, which when degraded result in physiologically acceptable degradation products, including the monomers. Anhydrides, amides, orthoesters or the like, by themselves or in combination with other monomers, may find use.
  • the polymers may be condensation polymers.
  • the polymers may be cross-linked or non-cross-linked, usually not more than lightly cross-linked, generally less than 5%, usually less than 1% cross-linked.
  • the polymers will include oxygen and nitrogen, particularly oxygen.
  • the oxygen may be present as oxy, e.g.
  • biodegrable polymers set forth in Heller, Biodegrable Polymers in Controlled Drug Delivery, in: CRC Critical
  • polyesters of interest include polymers of D-lactic acid, L-lactic acid, racemic lactic acid, glycolic acid, polycaprolactone, and combinations thereof.
  • L-lactate or D-lactate a slowly biodegrading polymer is achieved, while degradation is substantially enhanced with the racemate.
  • Copolymers of glycolic and lactic acid are of particular interest, where the rate of biodegradation is controlled by the ratio of glycolic to lactic acid.
  • the % of polylactic acid in the polylactic acid polyglycolic acid (PLGA) copolymer can be 0-100%, preferably about 15-85%, more preferably about 35-65%. In a particularly preferred embodiment, a 50/50 PLGA copolymer is used.
  • the most rapidly degraded copolymer has roughly equal amounts of glycolic and lactic acid, where either homopolymer is more resistant to degradation.
  • the ratio of glycolic acid to lactic acid will also affect the brittleness of in the implant, where a more flexible implant is desirable for larger geometries.
  • the size of the polymer particles is preferably about 1-100 ⁇ m in diameter, more preferably about 5-50 ⁇ m in diameter, more preferably about 9-12 ⁇ m in diameter, still more preferably about 10 ⁇ m in diameter.
  • the implant comprises hydroxypropyl methylcellulose (HPMC).
  • release modulators such as those described in U.S. Patent No.
  • 5,869,079 may be included in the implants.
  • the amount of release modulator employed will be dependent on the desired release profile, the activity of the modulator, and on the release profile of the immunosuppressive agent in the absence of modulator.
  • Other agents may be employed in the formulation for a variety of purposes.
  • buffering agents and preservatives may be employed.
  • Water soluble preservatives which may be employed include sodium bisulfite, sodium bisulfate, sodium thiosulfate, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate, phenylmercuric nitrate, methylparaben, polyvinyl alcohol and phenylethyl alcohol. These agents may be present in individual amounts of from about 0.001 to about 5% by weight and preferably about 0.01 to about 2%.
  • Suitable water soluble buffering agents that may be employed are sodium carbonate, sodium borate, sodium phosphate, sodium acetate, sodium bicarbonate, etc., as approved by the FDA for the desired route of administration. These agents may be present in amounts sufficient to maintain a pH of the system of between 2 to 9 and preferably 4 to 8. As such the buffering agent may be as much as 5% on a weight to weight basis of the total composition. Electrolytes such as sodium chloride and potassium chloride may also be included in the formulation. Where the buffering agent or enhancer is hydrophilic, it may also act as a release accelerator. Hydrophilic additives act to increase the release rates through faster dissolution of the material surrounding the drug particles, which increases the surface area of the drug exposed, thereby increasing the rate of drug bioerosion. Similarly, a hydrophobic buffering agent or enhancer dissolve more slowly, slowing the exposure of drug particles, and thereby slowing the rate of drug bioerosion.
  • the proportions of immunosuppressive agent, polymer, and any other modifiers may be empirically determined by formulating several implants with varying proportions.
  • a USP approved method for dissolution or release test can be used to measure the rate of release (USP 23; NF 18 (1995) pp. 1790-1798).
  • USP 23; NF 18 (1995) pp. 1790-1798 For example, using the infinite sink method, a weighed sample of the drug delivery system is added to a measured volume of a solution containing 0.9% NaCl in water, where the solution volume will be such that the drug concentration is after release is less than 5% of saturation. The mixture is maintained at 37°C and stirred slowly to maintain the implants in suspension.
  • the appearance of the dissolved drug as a function of time may be followed by various methods known in the art, such as spectrophotometrically, HPLC, mass spectroscopy, etc. until the absorbance becomes constant or until greater than 90% of the drug has been released.
  • the release kinetics of the drug delivery systems of the invention are dependent in part on the surface area of the implants. Larger surface area exposes more polymer to the eye, causing faster erosion and dissolution of the drug particles entrapped by the polymer.
  • the size and form of the implant can be used to control the rate of release, period of treatment, and drug concentration at the site of implantation. Larger implants will deliver a proportionately larger dose, but depending on the surface to mass ratio, may have a slower release rate.
  • the implants may be particles, sheets, patches, plaques, films, discs, fibers, microcapsules and the like and may be of any size or shape compatible with the selected site of insertion, as long as the implants have the desired release kinetics.
  • the implant to be inserted is formulated as a single particle.
  • the implant will not migrate from the insertion site following implantation.
  • the upper limit for the implant size will be determined by factors such as the desired release kinetics, location of the implant in the eye, toleration for the implant, size limitations on insertion, ease of handling, etc.
  • the vitreous chamber is able to accommodate relatively large implants of varying geometries, having diameters of 1 to 3 mm.
  • the implant is a cylindrical pellet (e.g., rod) with dimensions of about 2mm x 0.75mm diameter.
  • the implant is a cylindrical pellet (e.g., rod) with dimensions of about 1 mm x 380 ⁇ m diameter.
  • the implants will also preferably be at least somewhat flexible so as to facilitate both insertion of the implant in the eye and accommodation of the implant.
  • the total weight of the implant is preferably about 50-5000 ⁇ g, more preferably about 100-1000 ⁇ g. In one embodiment, the implant is about 500 ⁇ g. In a particularly preferred embodiment, the implant is about 1000 ⁇ g. In another particularly preferred embodiment, the implant is about 120 ⁇ g.
  • U.S. Pat. No. 5,869,079 further describes preferred implant sizes for particular regions of the eye, as well as preferred sizes for particular implant shapes.
  • a solid bioerodible implant for reducing or preventing transplant rejection in the eye comprising about 50% by weight of dexamethasone, about 15% by weight of hydroxypropyl methylcellulose (HPMC) and about 35% by weight of polylactic polyglycolic acid (PLGA).
  • HPMC hydroxypropyl methylcellulose
  • PLGA polylactic polyglycolic acid
  • a solid bioerodible implant for reducing or preventing transplant rejection in the eye comprising about 70% by weight of dexamethasone and about 30% by weight of polylactic polyglycolic acid (PLGA).
  • a solid bioerodible implant for reducing or preventing transplant rejection in the eye comprising about 50% by weight of dexamethasone and about 50% by weight of polylactic polyglycolic acid (PLGA).
  • the preferred supplier of PLGA is Boehringer Ingelheim and the preferred
  • PLGA products are Resomer RG 502 and Resomer RG 502H.
  • the solid bioerodible implant includes about
  • the solid bioerodible implant includes about
  • Useful techniques include phase separation methods, interfacial methods, extrusion methods, compression methods, molding methods, injection molding methods, heat press methods and the like.
  • compression methods are used to produce the implants of the invention.
  • compression methods use pressures of 50-150 psi, more preferably about 70-80 psi, even more preferably about 76 psi, and use temperatures of about 0°C to about 115°C, more preferably about 25°C.
  • extrusion methods are used.
  • implants produced by extrusion methods are heated to a temperature range of about 60°C to about 150°C for drug/polymer mixing, preferably about 85°C, preferably about 130°C, for a time period of about 0 to 1 hour, 0 to 30 minutes, 5-15 minutes, preferably about 10 minutes, preferably about 0 to 5 min, preferably about 1 hour.
  • the implants are then extruded at a temperature of about 60°C to about 130°C, preferably about 95°C, preferably about 85°C, preferably about 75°C.
  • kits for treating or preventing transplant rejection in the eye comprising a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer, wherein the drug delivery system is designed to be implanted in the eye.
  • the kit may also include instructions for use.
  • the bioerodible drug delivery systems as described herein are suitable for use in the kits of the invention.
  • the immunosuppressive agent is dexamethasone.
  • the invention is further described by the following nonlimiting examples.
  • Example 1 Effect of dexamethasone implant in animal penetrating keratoplasty model.
  • the objective of this study was to determine the efficacy of sustained release intraocular dexamethasone implanted in the anterior chamber of the rat eye at the end of cornea transplant surgery and compare it with local eye drop therapy.
  • the approximately 120 ⁇ g dexamethasone implant contained about 15% HPMC, 35% PLGA and 50% dexamethasone, and was prepared and tested in vitro as described in U.S. Patent No. 5,869,079 (See Example 1), which is specifically incorporated herein by reference in its entirety.
  • PGP Penetrating keratoplasty
  • Group #3 heavy inflammation was observed in AC, cornea endothelium, also in the stroma, and some in the epithelium. Corneas also showed edema due to destroyed endothelial cells. [00072] In Group #2 similar findings were observed.
  • dexamethasone powder (Upjohn) (particle sizes less than 10 ⁇ m in diameter) were mixed with 900 mg of 50/50 polylactic acid polyglycolic acid (PLGA) (particle sizes approximately 9-12 ⁇ m in diameter) at ambient temperature.
  • PLGA polylactic acid polyglycolic acid
  • a small Teflon® tube was filled with 900-1100 ⁇ g of the above mixture, and placed directly on the die cavity. The powder was pushed out of the tubing into the die cavity with a stainless steel wire and the tube and wire were removed from the die. The powder was pressed using a tablet press (approximately 76 psi), ejected with the ejector switch, and removed with tweezers. The resulting pellet was approximately 2mm x 0.75mm. [00076] Release of dexamethasone from the DEX PS DDS® system was measured.
  • One DDS was placed in a glass vial filled with receptor medium (0.9% NaCl in water).
  • receptor medium (0.9% NaCl in water).
  • the receptor medium volume was chosen so that the concentration would never exceed 5% of saturation.
  • the glass vial was placed into a shaking water bath at 37°C. Samples were taken for HPLC analysis from the vial at defined time points. The HPLC method was as described in USP 23(1995) pp.1791 -1798. The concentration values were used to calculate the cumulative release data, as shown in Table 2.
  • Table 2 shows an almost linear in vitro release of dexamethasone over a one month period of time.
  • the data indicate that the DEX PS DDS® releases dexamethasone to the vitreous in concentrations above 0.01 ⁇ g/ml for an extended period of time. Further, the data indicate that placement of the device with trocar results in much higher levels of drug release than with placement with forceps, most likely due to placement of the device deeper within the vitreous. The data at two, four, six, and 24 hours in Table 4 shows an initial spike of drug release.
  • Example 4 Manufacture And In vitro Testing Of 50/50 Dexamethasone PLGA Posterior Segment Drug Delivery System

Abstract

Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a biorodible polymer.

Description

METHODS FOR REDUCING OR PREVENTING TRANSPLANT REJECTION IN
THE EYE AND INTRAOCULAR IMPLANTS FOR USE THEREFOR
INVENTOR: VERNON G. WONG
[00001] This application claims priority to U.S. Provisional Application serial No.
60/250,023, filed November 29, 2000, titled "Methods for Preventing Transplant Rejection in the Eye and Intraocular Implants for Use Thereof and U.S. Provisional Application Serial No. 60/298,253, filed June 12, 2001, titled "Intraocular Dexamethasone Deliver System for Corneal Transplantation in Animal Model." Both of these Provisional applications are incorporated herein by reference.
TECHNICAL FIELD [00002] This invention relates to the field of transplantation, in particular transplantation of components of the eye, and methods for preventing transplant rejection.
BACKGROUND ART
[00003] Certain conditions and diseases of the eye, such as corneal failure, keratoconus, corneal dystrophies, scarring, age related macular degeneration (AMD) and retinitis pigmentosa, have been treated using ocular transplant procedures such as corneal and retinal pigment epithelial (RPE) transplants. Transplant rejection is one of the problems which may arise from transplant procedures (Enzmann V et al. (1998).
"Immunological problems of transplantation into the subretinal space." ActaAnat (Basel).
162(2-3): 178-83). In spite of the overall success with corneal transplants, a substantial percentage of corneal grafts experience at least one rejection episode (PCT/US97/21393).
[00004] One of the problems with present immunosuppressive drug therapy is the inability to achieve adequate intraocular drug concentrations. Systemic immunosuppression may require prolonged exposure to high plasma concentrations so that therapeutic levels can be achieved in the eye. Overall drug delivery to the eye may be poor due to the short drug plasma half-life limiting exposure into intraocular tissues. In addition, this may turn lead to numerous negative side effects.
[00005] There is a continued need for improved intraocular sustained release drug therapies for patients following ocular transplant procedures. [00006] All references cited in this patent are incorporated herein by reference in their entirety.
DISCLOSURE OF THE INVENTION [00007] One embodiment of the present invention provides a method for reducing or preventing transplant rejection in the eye of an individual, where the method comprises: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer. [00008] Another embodiment of the invention provides a method for reducing or preventing transplant rejection in the eye of an individual, where the method comprises: a) performing an ocular transplant procedure; and b) implanting a solid body into the eye, said body comprising particles of an immunosuppressive agent entrapped within a bioerodible polymer, whereby said agent is released from the body by erosion of the polymer. [00009] Another embodiment of the invention provides a method which includes placing in an eye of an individual a bioerodible drug delivery system, where the bioerodible drug delivery system includes an immunosuppressive agent and a bioerodible polymer; and where the eye of the individual has undergone or is undergoing an ocular transplant procedure. This method may be used to reduce or prevent transplant rejection. [00010] Another embodiment of the invention provides a kit comprising: a) a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer, wherein the drug delivery system is designed to be implanted in the eye; and b) instructions for use. This kit may be used to reduce or prevent transplant rejection.
MODES FOR CARRYING OUT THE INVENTION Definitions
[00011] An "ocular transplant procedure," as used herein, refers to any transplant procedure performed in the eye. Non-limiting examples of ocular transplant procedures include, but are not limited to, retinal pigment epithelium (RPE) transplant and cornea transplant. It includes autograft, allograft and xenograft transplant procedures. [00012] "Immunosuppressive agent," "agent," "immunosuppressive drug," and
"drug," are used interchangeably herein, and refer to any agent which inhibits or prevents an immune response against the transplanted tissue following a transplant procedure. Exemplary agents include, but are not limited to, dexamethasone, cyclosporin A, azathioprine, brequinar, gusperimus, 6-mercaptopurine, mizoribine, rapamycin, tacrolimus
(FK-506), folic acid analogs (e.g., denopterin, edatrexate, methotrexate, piritrexim, pteropterin, Tomudex®, trimetrexate), purine analogs (e.g., cladribine, fludarabine, 6- mercaptopurine, thiamiprine, thiaguanine), pyrimidine analogs (e.g., ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, doxifluridine, emitefur, enocitabine, floxuridine, fluorouracil, gemcitabine, tegafur), fluocinolone, triaminolone, anecortave acetate, flurometholone, medrysone, and prednislone.
[00013] An "implant" and a "drug delivery system," are used interchangeably herein, and include any bioerodible device for implantation in the eye which is capable of delivering a therapeutic level of drug to the eye.
[00014] To "implant" to "place" and to "insert" are equivalent as used in this patent and mean to place an object in the desired site by any means capable of placing the object at that site.
[00015] By "therapeutic level" is meant a level of drug sufficient to prevent, inhibit, or reduce the level of transplant rejection in the eye.
[00016] The term "bioerodible polymer" refers to polymers which degrade in vivo, and wherein erosion of the polymer over time is required to achieve the agent release kinetics according to the invention. Specifically, hydrogels such as methylcellulose which act to release drug through polymer swelling are specifically excluded from the term
"bioerodible polymer". The terms "bioerodible" and "biodegradable" are equivalent and are used interchangeably in this patent.
[00017] An "individual" is a vertebrate, preferably mammal, more preferably a human. Mammals include, but are not limited to, humans, rodents, sport animals and pets, such as rats, dogs, and horses.
Methods for Reducing or Preventing Transplant Rejection
[00018] Intraocular immunosuppressive drug delivery systems made of a biodegradable polymer matrix are provided which can release drug loads over various programmed time periods. When inserted into the eye these drug delivery systems provide therapeutic levels of immunosuppressive agent for reducing or preventing transplant rejection.
[00019] Accordingly, one embodiment of the present invention provides a method for reducing or preventing transplant rejection in the eye of an individual, comprising: performing an ocular transplant procedure; and implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer. [00020] In another embodiment of the invention, a method for reducing or preventing transplant rejection in the eye of an individual is provided, comprising: performing an ocular transplant procedure; and implanting a solid body into the eye, said body comprising particles of an immunosuppressive agent entrapped within a bioerodible polymer, whereby said agent is released from the body by erosion of the polymer. [00021] Ocular transplant procedures which may be used with the methods of the invention include, but are not limited to, cornea transplant and RPE transplant. Methods for performing these transplant procedures are well known in the art. Methods for performing RPE transplants are described in, for example, U.S. Pat. Nos. 5,962,027, 6,045,791 , and 5,941 ,250 and in Eye Graefes Arch Clin Exp Opthalmol 1997 Mar; 235(3): 149-58; Biochem Biophys Res Commun 2000 Feb 24; 268(3): 842-6; Opthalmic Surg 1991 Feb; 22(2): 102-8. Methods for performing corneal transplants are described in, for example, U.S. Pat. No. 5,755,785, and in Eye 1995; 9 (Pt 6 Su):6-12; Curr Opin Opthalmol 1992 Aug; 3 (4): 473-81; Ophthalmic Surg Lasers 1998 Apr; 29 (4): 305-8; Ophthalmology 2000 Apr; 107 (4): 719-24; and Jpn J Ophthalmol 1999 Nov-Dec; 43(6): 502-8. Exemplary methods for corneal and RPE transplantation in animal models are described in Examples 1 , 4 and 5 below. In a preferred embodiment, the ocular transplant procedure is a cornea transplant. In another preferred embodiment, the ocular transplant procedure is an RPE procedure.
[00022] The drug delivery system may be implanted at various sites in the eye, depending on the size, shape and formulation of the implant, the type of transplant procedure, etc. Suitable sites include but are not limited to the anterior chamber, anterior segment, posterior chamber, posterior segment, vitreous cavity, suprachoroidal space, subconjunctiva, episcleral, intracomeal, epicorneal and sclera. In a preferred embodiment, the drug delivery system is placed in the anterior chamber of the eye. In another preferred embodiment, the drug delivery system is placed in the vitreous cavity. [00023] The implants may be inserted into the eye by a variety of methods, including placement by forceps or by trocar following making an incision in the sclera (for example, a 2-3 mm incision) or other suitable site. In some cases, the implant may be able to be placed by trocar without making a separate incision, but instead by punching a hole directly into the eye with the trocar. The method of placement may influence the drug release kinetics. For example, implanting the device into the vitreous with a trocar may result in placement of the device deeper within the vitreous than placement by forceps, which may result in the implant being closer to the edge of the vitreous. The location of the implanted device may influence the concentration gradients of drug surrounding the device, and thus influence the release rates (e.g., a device placed closer to the edge of the vitreous may result in a slower release rate).
[00024] U.S. Pat. No. 5,869,079 further describes locations for intraocular implants and methods for insertion (see in particular col. 6-7).
[00025] In one embodiment, the implant delivers the immunosuppressive agent for at least about 5 days. In other embodiments, the implant delivers the immunosuppressive agent for at least about one week, at least about 2 weeks, at least about 3 weeks, at least about four weeks, at least about five weeks, at least about six weeks, at least about seven weeks, at least about eight weeks, at least about nine weeks, at least about 10 weeks, and at least about 12 weeks. The preferred duration of drug release may be determined by the type of transplant, the medical history of the patient, etc. In one embodiment, drug release may occur for up to 6 months, or one year, or longer. In one embodiment, more than one implant may be sequentially implanted into the vitreous in order to maintain drug concentrations for even longer periods. In one embodiment, more than one implant may be sequentially implanted into the eye in order to maintain therapeutic drug concentrations for longer periods. Co-owned U.S. Pat. Appl. Serial No. 09/693,008, titled "Methods For Treating Inflammation-Mediated Conditions of the Eye," to Wong et al. filed October 20, 2000, which is expressly incorporated herein by reference in its entirety, further describes implants and methods for making the implants which can achieve and maintain particular drug concentrations for programmed extended periods of time. [00026] The methods of the invention are preferably performed on vertebrates, preferably mammal, more preferably a human. Mammals include, but are not limited to, humans, rodents, sport animals and pets, such as rats, dogs and horses.
Implants
[00027] The formulation of the implants for use in the invention may vary according to the preferred drug release profile, the particular immunosuppressive agent used, the transplant procedure, the medical history of the patient and other factors affecting the formulation.
[00028] The implants of the invention are formulated with particles of the immunosuppressive agent associated with the bioerodible polymer matrix. In a preferred embodiment the immunosuppressive agent is entrapped within the bioerodible polymer matrix. Without being bound by theory, we hypothesize that release of the agent is achieved by erosion of the polymer followed by exposure of previously entrapped agent particles to the eye, and subsequent dissolution and release of agent. The release kinetics achieved by this form of drug release are different than that achieved through formulations which release drug through polymer swelling, such as with hydrogels such as methylcellulose. In that case, the drug is not released through polymer erosion, but through polymer swelling, which release drug as liquid diffuses through the pathways exposed.
The parameters which may determine the release kinetics include the size of the drug particles, the water solubility of the drug, the ratio of drug to polymer, the method of manufacture, the surface area exposed, and the erosion rate of the polymer.
[00029] In a preferred embodiment the immunosuppressive agent is selected from the group consisting of dexamethasone, cyclosporin A, azathioprine, brequinar, gusperimus, 6-mercaptopurine, mizoribine, rapamycin, tacrolimus (FK-506), folic acid analogs (e.g., denopterin, edatrexate, methotrexate, piritrexim, pteropterin, Tomudex®, trimetrexate), purine analogs (e.g., cladribine, fludarabine, 6-mercaptopurine, thiamiprine, thiaguanine), pyrimidine analogs (e.g., ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, doxifluridine, emitefur, enocitabine, floxuridine, fluorouracil, gemcitabine, tegafur) fluocinolone, triaminolone, anecortave acetate, fluorometholone, medrysone, and prednislone. In a preferred embodiment, the immunosuppressive agent is dexamethasone.
In another preferred embodiment, the immunosuppressive agent is cyclosporin A. In another embodiment, the bioerodible implant comprises more than one immunosuppressive agent.
[00030] The implants may further comprise one or more additional therapeutic agents, such as antibiotics or antiinflammatory agents. Specific antibiotics include, but are not limited to:
Antibacterial antibiotics:
[00031] Aminoglycosides (e.g., amikacin, apramycin, arbekacin, bambermycins, butirosin, dibekacin, dihydrostreptomycin, fortimicin(s), gentamicin, isepamicin, kanamycin, micronomicin, neomycin, neomycin undecylenate, netilmicin, paromomycin, ribostamycin, sisomicin, spectinomycin, streptomycin, tobramycin, trospectomycin), amphenicols (e.g., azidamfenicol, chloramphenicol, florfenicol, thiamphenicol), ansamycins (e.g., rifamide, rifampin, rifamycin sv, rifapentine, rifaximin), β-lactams (e.g., carbacephems (e.g., loracarbef), carbapenems (e.g., biapenem, imipenem, meropenem, panipenem), cephalosporins (e.g., cefaclor, cefadroxil, cefamandole, cefatrizine, cefazedone, cefazolin, cefcapene pivoxil, cefclidin, cefdinir, cefditoren, cefepime, cefetamet, cefixime, cefmenoxime, cefodizime, cefonicid, cefoperazone, ceforanide, cefotaxime, cefotiam, cefozopran, cefpimizole, cefpiramide, cefpirome, cefpodoxime proxetil, cefprozil, cefroxadine, cefsulodin, ceftazidime, cefteram, ceftezole, ceftibuten, ceftizoxime, ceftriaxone, cefuroxime, cefuzonam, cephacetrile sodium, cephalexin, cephaloglycin, cephaloridine, cephalosporin, cephalothin, cephapirin sodium, cephradine, pivcefalexin), cephamycins (e.g., cefbuperazone, cefmetazole, cefminox, cefotetan, cefoxitin), monobactams (e.g., aztreonam, carumonam, tigemonam), oxacephems, flomoxef, moxalactam), penicillins (e.g., amdinocillin, amdinocillin pivoxil, amoxicillin, ampicillin, apalcillin, aspoxicillin, azidocillin, azlocillin, bacampicillin, benzylpenicillinic acid, benzylpenicillin sodium, carbenicillin, carindacillin, clometocillin, cloxacillin, cyclacillin, dicloxacillin, epicillin, fenbenicillin, floxacillin, hetacillin, lenampicillin, metampicillin, methicillin sodium, mezlocillin, nafcillin sodium, oxacillin, penamecillin, penethamate hydriodide, penicillin g benethamine, penicillin g benzathine, penicillin g benzhydrylamine, penicillin g calcium, penicillin g hydrabamine, penicillin g potassium, penicillin g procaine, penicillin n, penicillin o, penicillin v, penicillin v benzathine, penicillin v hydrabamine, penimepicycline, phenethicillin potassium, piperacillin, pivampicillin, propicillin, quinacillin, sulbenicillin, sultamicillin, talampicillin, temocillin, ticarcillin), other (e.g., ritipenem), lincosamides (e.g., clindamycin, lincomycin), macrolides (e.g., azithromycin, carbomycin, clarithromycin, dirithromycin, erythromycin, erythromycin acistrate, erythromycin estolate, erythromycin glucoheptonate, erythromycin lactobionate, erythromycin propionate, erythromycin stearate, josamycin, leucomycins, midecamycins, miokamycin, oleandomycin, primycin, rokitamycin, rosaramicin, roxithromycin, spiramycin, troleandomycin), polypeptides (e.g., amphomycin, bacitracin, capreomycin, colistin, enduracidin, enviomycin, fusafungine, gramicidin s, gramicidin(s), mikamycin, polymyxin, pristinamycin, ristocetin, teicoplanin, thiostrepton, tuberactinomycin, tyrocidine, tyrothricin, vancomycin, viomycin, virginiamycin, zinc bacitracin), tetracyclines (e.g., apicycline, chlortetracycline, clomocycline, demeclocycline, doxycycline, guamecycline, lymecycline, meclocycline, methacycline, minocycline, oxytetracycline, penimepicycline, pipacycline, rolitetracycline, sancycline, tetracycline), and others (e.g., cycloserine, mupirocin, tuberin).
Synthetic antibacterials:
[00032] 2,4-Diaminopyrimidines (e.g., brodimoprim, tetroxoprim, trimethoprim), nitrofurans (e.g., furaltadone, furazolium chloride, nifuradene, nifuratel, nifurfoline, nifurpirinol, nifurprazine, nifurtoinol, nitrofurantoin), quinolones and analogs (e.g., cinoxacin, ciprofloxacin, clinafloxacin, difloxacin, enoxacin, fleroxacin, flumequine, grepafloxacin, lomefloxacin, miloxacin, nadifloxacin, nalidixic acid, norfloxacin, ofloxacin, oxolinic acid, pazufloxacin, pefloxacin, pipemidic acid, piromidic acid, rosoxacin, rufloxacin, sparfloxacin, temafloxacin, tosufloxacin, trovafloxacin), sulfonamides (e.g., acetyl sulfamethoxypyrazine, benzylsulfamide, chloramine-b, chloramine-t, dichloramine t, n2-formylsulfisomidine, n4-β-d-glucosylsulfanilamide, mafenide, 4'-(methylsulfamoyl)sulfanilanilide, noprylsulfamide, phthalylsulfacetamide, phthalylsulfathiazole, salazosulfadimidine, succinylsulfathiazole, sulfabenzamide, sulfacetamide, sulfachlorpyridazine, sulfachrysoidine, sulfacytine, sulfadiazine, sulfadicramide, sulfadimethoxine, sulfadoxine, sulfaethidole, sulfaguanidine, sulfaguanol, sulfalene, sulfaloxic acid, sulfamerazine, sulfameter, sulfamethazine, sulfamethizole, sulfamethomidine, sulfamethoxazole, sulfamethoxypyridazine, sulfametrole, sulfamidochrysoidine, sulfamoxole, sulfanilamide, 4-sulfanilamidosalicylic acid, n4- sulfanilylsulfanilamide, sulfanilylurea, n-sulfanilyl-3,4-xylamide, sulfanitran, sulfaperine, sulfaphenazole, sulfaproxyline, sulfapyrazine, sulfapyridine, sulfasomizole, sulfasymazine, sulfathiazole, sulfathiourea, sulfatolamide, sulfisomidine, sulfisoxazole) sulfones (e.g., acedapsone, acediasulfone, acetosulfone sodium, dapsone, diathymosulfone, glucosulfone sodium, solasulfone, succisulfone, sulfanilic acid, p-sulfanilylbenzylamine, sulfoxone sodium, thiazolsulfone), and others (e.g., clofoctol, hexedine, methenamine, methenamine anhydromethylene-citrate, methenamine hippurate, methenamine mandelate, methenamine sulfosalicylate, nitroxoline, taurolidine, xibornol).
Antifungal antibiotics:
[00033] Polyenes (e.g. , amphotericin b, candicidin, dermostatin, filipin, fungichromin, hachimycin, hamycin, lucensomycin, mepartricin, natamycin, nystatin, pecilocin, perimycin), others (e.g., azaserine, griseofulvin, oligomycins, neomycin undecylenate, pyrrolnitrin, siccanin, tubercidin, viridin). Synthetic antifungals:
[00034] Allylamines (e.g. , butenafine, naftifine, terbinafine), imidazoles (e.g. , bifonazole, butoconazole, chlordantoin, chlormidazole, cloconazole, clotrimazole, econazole, enilconazole, fenticonazole, flutrimazole, isoconazole, ketoconazole, lanoconazole, miconazole, omoconazole, oxiconazole nitrate, sertaconazole, sulconazole, tioconazole), thiocarbamates (e.g., tolciclate, tolindate, tolnaftate), triazoles (e.g., fluconazole, itraconazole, saperconazole, terconazole) others (e.g., acrisorcin, amorolfine, biphenamine, bromosalicylchloranilide, buclosamide, calcium propionate, chlorphenesin, ciclopirox, cloxyquin, coparaffinate, diamthazole dihydrochloride, exalamide, flucytosine, halethazole, hexetidine, loflucarban, nifuratel, potassium iodide, propionic acid, pyrithione, sahcylanilide, sodium propionate, sulbentine, tenonitrozole, triacetin, ujothion, undecylenic acid, zinc propionate). Antineoplastic:
[00035] Antibiotics and analogs (e.g., aclacinomycins, actinomycin fl5 anthramycin, azaserine, bleomycins, cactinomycin, carubicin, carzinophilin, chromomycins, dactinomycin, daunorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, idarubicin, menogaril, mitomycins, mycophenolic acid, nogalamycin, olivomycines, peplomycin, pirarubicin, plicamycin, porfiromycin, puromycin, streptonigrin, streptozocin, tubercidin, zinostatin, zorubicin), antimetabolites (e.g. folic acid analogs (e.g., denopterin, edatrexate, methotrexate, piritrexim, pteropterin, Tomudex®, trimetrexate), purine analogs (e.g., cladribine, fludarabine, 6-mercaptopurine, thiamiprine, thioguanine), pyrimidine analogs (e.g., ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, doxifluridine, emitefur, enocitabine, floxuridine, fluorouracil, gemcitabine, tagafur). Specific antiinflammatory agents include, but are not limited to: Steroidal antiinflammatory agents:
[00036] 21-acetoxypregnenolone, alclometasone, algestone, amcinonide, beclomethasone, betamethasone, budesonide, chloroprednisone, clobetasol, clobetasone, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacort, desonide, desoximetasone, dexamethasone, diflorasone, diflucortolone, difluprednate, enoxolone, fluazacort, flucloronide, flumefhasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortolone, fluorometholone, fluperolone acetate, fluprednidene acetate, fluprednisolone, flurandrenolide, fluticasone propionate, formocortal, halcinonide, halobetasol propionate, halometasone, halopredone acetate, hydrocortamate, hydrocortisone, loteprednol etabonate, mazipredone, medrysone, meprednisone, methylprednisolone, mometasone furoate, paramethasone, prednicarbate, prednisolone, prednisolone 25-diethylamino-acetate, prednisolone sodium phosphate, prednisone, prednival, prednylidene, rimexolone, tixocortol, triamcinolone, triamcinolone acetonide, triamcinolone benetonide, and triamcinolone hexacetonide.
Non-steroidal antiinflammatory agents:
[00037] Aminoarylcarboxylic acid derivatives (e.g., enfenamic acid, etofenamate, flufenamic acid, isonixin, meclofenamic acid, mefenamic acid, niflumic acid, talniflumate, terofenamate, tolfenamic acid), arylacetic acid derivatives (e.g., aceclofenac, acemetacin, alclofenac, amfenac, amtolmetin guacil, bromfenac, bufexamac, cinmetacin, clopirac, diclofenac sodium, etodolac, felbinac, fenclozic acid, fentiazac, glucametacin, ibufenac, indomethacin, isofezolac, isoxepac, lonazolac, metiazinic acid, mofezolac, oxametacine, pirazolac, proglumetacin, sulindac, tiaramide, tolmetin, tropesin, zomepirac), arylbutyric acid derivatives (e.g., bumadizon, butibufen, fenbufen, xenbucin), arylcarboxylic acids
(e.g., clidanac, ketorolac, tinoridine), arylpropionic acid derivatives (e.g., alminoprofen, benoxaprofen, bermoprofen, bucloxic acid, carprofen, fenoprofen, flunoxaprofen, flurbiprofen, ibuprofen, ibuproxam, indoprofen, ketoprofen, loxoprofen, naproxen, oxaprozin, piketoprolen, pirprofen, pranoprofen, protizinic acid, suprofen, tiaprofenic acid, ximoprofen, zaltoprofen), pyrazoles (e.g., difenamizole, epirizole), pyrazolones (e.g., apazone, benzpiperylon, feprazone, mofebutazone, morazone, oxyphenbutazone, phenylbutazone, pipebuzone, propyphenazone, ramifenazone, suxibuzone, thiazolinobutazone), salicylic acid derivatives (e.g., acetaminosalol, aspirin, benorylate, bromosaligenin, calcium acetylsalicylate, diflunisal, etersalate, fendosal, gentisic acid, glycol salicylate, imidazole salicylate, lysine acetylsalicylate, mesalamine, morpholine salicylate, 1-naphthyl salicylate, olsalazine, parsalmide, phenyl acetylsalicylate, phenyl salicylate, salacetamide, salicylamide o-acetic acid, salicylsulfuric acid, salsalate, sulfasalazine), thiazinecarboxamides (e.g., ampiroxicam, droxicam, isoxicam, lornoxicam, piroxicam, tenoxicam), 6-acetamidocaproic acid, s-adenosylmethionine,
3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, α-bisabolol, bucolome, difenpiramide, ditazol, emorfazone, fepradinol, guaiazulene, nabumetone, nimesulide, oxaceprol, paranyline, perisoxal, proquazone, superoxide dismutase, tenidap, and zileuton.
[00038] The immunosuppressive agent is preferably from about 10 to 90% by weight of the implant. More preferably, the agent is from about 50 to about 80% by weight of the implant. In a preferred embodiment, the agent comprises about 50% by weight of the implant. In a preferred embodiment, the agent comprises about 70% by weight of the implant.
[00039] The implants are preferably monolithic, i.e. having the immunosuppressive agent homogeneously distributed through the polymeric matrix. In this patent, by homogeneously distributed we mean that the immunosuppressive agent is distributed evenly enough that no detrimental fluctuations in rate of immunosuppressive agent release occur because of uneven distribution of the immunosuppressive agent in the polymer matrix. The selection of the polymeric composition to be employed will vary with the desired release kinetics, the location of the implant, patient tolerance, the nature of the transplant procedure and the like. Characteristics of the polymers will include biodegradabihty at the site of implantation, compatibility with the agent of interest, ease of encapsulation, water insolubility, and the like. Preferably, the polymeric matrix will not be fully degraded until the drug load has been released. The polymer will usually comprise at least about 10, more usually at least about 20 weight percent of the implant. In one embodiment, the implant comprises more than one polymer.
[00040] Biodegradable polymeric compositions which may be employed may be organic esters or ethers, which when degraded result in physiologically acceptable degradation products, including the monomers. Anhydrides, amides, orthoesters or the like, by themselves or in combination with other monomers, may find use. The polymers may be condensation polymers. The polymers may be cross-linked or non-cross-linked, usually not more than lightly cross-linked, generally less than 5%, usually less than 1% cross-linked. For the most part, besides carbon and hydrogen, the polymers will include oxygen and nitrogen, particularly oxygen. The oxygen may be present as oxy, e.g. , hydroxy or ether, carbonyl, e.g., non-oxo-carbonyl, such as carboxylic acid ester, and the like. The nitrogen may be present as amide, cyano and amino. The biodegrable polymers set forth in Heller, Biodegrable Polymers in Controlled Drug Delivery, in: CRC Critical
Reviews in Therapeutic Drug Carrier Systems, Vol. 1. CRC Press, Boca Raton, FL (1987), may be used.
[00041] Of particular interest are polymers of hydroxyaliphatic carboxylic acids, either homo- or copolymers, and polysaccharides. Included among the polyesters of interest are polymers of D-lactic acid, L-lactic acid, racemic lactic acid, glycolic acid, polycaprolactone, and combinations thereof. By employing the L-lactate or D-lactate, a slowly biodegrading polymer is achieved, while degradation is substantially enhanced with the racemate. Copolymers of glycolic and lactic acid are of particular interest, where the rate of biodegradation is controlled by the ratio of glycolic to lactic acid. The % of polylactic acid in the polylactic acid polyglycolic acid (PLGA) copolymer can be 0-100%, preferably about 15-85%, more preferably about 35-65%. In a particularly preferred embodiment, a 50/50 PLGA copolymer is used. The most rapidly degraded copolymer has roughly equal amounts of glycolic and lactic acid, where either homopolymer is more resistant to degradation. The ratio of glycolic acid to lactic acid will also affect the brittleness of in the implant, where a more flexible implant is desirable for larger geometries. The size of the polymer particles is preferably about 1-100 μm in diameter, more preferably about 5-50 μm in diameter, more preferably about 9-12 μm in diameter, still more preferably about 10 μm in diameter.
[00042] Among the polysaccharides of interest are calcium alginate, and functionalized celluloses, particularly carboxymethylcellulose esters characterized by being biodegradable, water insoluble, a molecular weight of about 5 kD to 500 kD, etc. In one embodiment, the implant comprises hydroxypropyl methylcellulose (HPMC). [00043] Additionally, release modulators such as those described in U.S. Patent No.
5,869,079 may be included in the implants. The amount of release modulator employed will be dependent on the desired release profile, the activity of the modulator, and on the release profile of the immunosuppressive agent in the absence of modulator. [00044] Other agents may be employed in the formulation for a variety of purposes.
For example, buffering agents and preservatives may be employed. Water soluble preservatives which may be employed include sodium bisulfite, sodium bisulfate, sodium thiosulfate, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate, phenylmercuric nitrate, methylparaben, polyvinyl alcohol and phenylethyl alcohol. These agents may be present in individual amounts of from about 0.001 to about 5% by weight and preferably about 0.01 to about 2%. Suitable water soluble buffering agents that may be employed are sodium carbonate, sodium borate, sodium phosphate, sodium acetate, sodium bicarbonate, etc., as approved by the FDA for the desired route of administration. These agents may be present in amounts sufficient to maintain a pH of the system of between 2 to 9 and preferably 4 to 8. As such the buffering agent may be as much as 5% on a weight to weight basis of the total composition. Electrolytes such as sodium chloride and potassium chloride may also be included in the formulation. Where the buffering agent or enhancer is hydrophilic, it may also act as a release accelerator. Hydrophilic additives act to increase the release rates through faster dissolution of the material surrounding the drug particles, which increases the surface area of the drug exposed, thereby increasing the rate of drug bioerosion. Similarly, a hydrophobic buffering agent or enhancer dissolve more slowly, slowing the exposure of drug particles, and thereby slowing the rate of drug bioerosion.
[00045] The proportions of immunosuppressive agent, polymer, and any other modifiers may be empirically determined by formulating several implants with varying proportions. A USP approved method for dissolution or release test can be used to measure the rate of release (USP 23; NF 18 (1995) pp. 1790-1798). For example, using the infinite sink method, a weighed sample of the drug delivery system is added to a measured volume of a solution containing 0.9% NaCl in water, where the solution volume will be such that the drug concentration is after release is less than 5% of saturation. The mixture is maintained at 37°C and stirred slowly to maintain the implants in suspension. The appearance of the dissolved drug as a function of time may be followed by various methods known in the art, such as spectrophotometrically, HPLC, mass spectroscopy, etc. until the absorbance becomes constant or until greater than 90% of the drug has been released.
[00046] The release kinetics of the drug delivery systems of the invention are dependent in part on the surface area of the implants. Larger surface area exposes more polymer to the eye, causing faster erosion and dissolution of the drug particles entrapped by the polymer. The size and form of the implant can be used to control the rate of release, period of treatment, and drug concentration at the site of implantation. Larger implants will deliver a proportionately larger dose, but depending on the surface to mass ratio, may have a slower release rate. The implants may be particles, sheets, patches, plaques, films, discs, fibers, microcapsules and the like and may be of any size or shape compatible with the selected site of insertion, as long as the implants have the desired release kinetics.
Preferably, the implant to be inserted is formulated as a single particle. Preferably, the implant will not migrate from the insertion site following implantation. The upper limit for the implant size will be determined by factors such as the desired release kinetics, location of the implant in the eye, toleration for the implant, size limitations on insertion, ease of handling, etc. For example, the vitreous chamber is able to accommodate relatively large implants of varying geometries, having diameters of 1 to 3 mm. In a preferred embodiment, the implant is a cylindrical pellet (e.g., rod) with dimensions of about 2mm x 0.75mm diameter. In another preferred embodiment, the implant is a cylindrical pellet (e.g., rod) with dimensions of about 1 mm x 380 μm diameter. The implants will also preferably be at least somewhat flexible so as to facilitate both insertion of the implant in the eye and accommodation of the implant. The total weight of the implant is preferably about 50-5000 μg, more preferably about 100-1000 μg. In one embodiment, the implant is about 500 μg. In a particularly preferred embodiment, the implant is about 1000 μg. In another particularly preferred embodiment, the implant is about 120 μg. U.S. Pat. No. 5,869,079 further describes preferred implant sizes for particular regions of the eye, as well as preferred sizes for particular implant shapes.
[00047] In a preferred embodiment, a solid bioerodible implant for reducing or preventing transplant rejection in the eye is provided, comprising about 50% by weight of dexamethasone, about 15% by weight of hydroxypropyl methylcellulose (HPMC) and about 35% by weight of polylactic polyglycolic acid (PLGA).
[00048] In another preferred embodiment, a solid bioerodible implant for reducing or preventing transplant rejection in the eye is provided, comprising about 70% by weight of dexamethasone and about 30% by weight of polylactic polyglycolic acid (PLGA). [00049] In another preferred embodiment, a solid bioerodible implant for reducing or preventing transplant rejection in the eye is provided, comprising about 50% by weight of dexamethasone and about 50% by weight of polylactic polyglycolic acid (PLGA). [00050] The preferred supplier of PLGA is Boehringer Ingelheim and the preferred
PLGA products are Resomer RG 502 and Resomer RG 502H.
[00051] In a preferred embodiment, the solid bioerodible implant includes about
50% by weight of dexamethasone, about 15% by weight of hydroxypropyl methylcellulose (HPMC) and about 35% by weight of Resomer RG 502H PLGA. [00052] In a preferred embodiment, the solid bioerodible implant includes about
60% by weight of dexamethasone, about 30% by weight of Resomer RG 502H PLGA, and about 10% by weight of Resomer RG 502 PLGA. Methods for making the implants
[00053] Various techniques may be employed to produce the implants. Useful techniques include phase separation methods, interfacial methods, extrusion methods, compression methods, molding methods, injection molding methods, heat press methods and the like.
[00054] Choice of the technique and manipulation of the technique parameters employed to produce the implants can influence the release rates of the drug. Room temperature compression methods result in an implant with discrete microparticles of drug and polymer interspersed. Extrusion methods result in implants with a progressively more homogenous dispersion of the drug within the polymer, as the production temperature is increased. When using extrusion methods, the polymer and drug are chosen to as to be stable at the temperatures required for manufacturing, usually at least about 85°C. Extrusion methods use temperatures of about 25°C to about 150°C, more preferably about 65°C to about 130°C. Generally, compression methods yield implants with faster release rates than extrusion methods, and higher temperatures yield implants with slower release rates.
[00055] In a preferred embodiment, compression methods are used to produce the implants of the invention. Preferably, compression methods use pressures of 50-150 psi, more preferably about 70-80 psi, even more preferably about 76 psi, and use temperatures of about 0°C to about 115°C, more preferably about 25°C. In another preferred embodiment, extrusion methods are used. Preferably, implants produced by extrusion methods are heated to a temperature range of about 60°C to about 150°C for drug/polymer mixing, preferably about 85°C, preferably about 130°C, for a time period of about 0 to 1 hour, 0 to 30 minutes, 5-15 minutes, preferably about 10 minutes, preferably about 0 to 5 min, preferably about 1 hour. Preferably, the implants are then extruded at a temperature of about 60°C to about 130°C, preferably about 95°C, preferably about 85°C, preferably about 75°C.
[00056] U.S. Pat. No. 4,997,652 further describes suitable methods for making the implants of the invention, and is herein incorporated by reference in its entirety.
Kit for the administration of the implants
[00057] In another aspect of the invention, a kit for treating or preventing transplant rejection in the eye is provided, comprising a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer, wherein the drug delivery system is designed to be implanted in the eye. The kit may also include instructions for use. [00058] The bioerodible drug delivery systems as described herein are suitable for use in the kits of the invention. In a preferred embodiment, the immunosuppressive agent is dexamethasone. [00059] The invention is further described by the following nonlimiting examples.
EXAMPLES
Example 1. Effect of dexamethasone implant in animal penetrating keratoplasty model.
[00060] The objective of this study was to determine the efficacy of sustained release intraocular dexamethasone implanted in the anterior chamber of the rat eye at the end of cornea transplant surgery and compare it with local eye drop therapy. The approximately 120 μg dexamethasone implant contained about 15% HPMC, 35% PLGA and 50% dexamethasone, and was prepared and tested in vitro as described in U.S. Patent No. 5,869,079 (See Example 1), which is specifically incorporated herein by reference in its entirety.
[00061] In order to create a very high risk of cornea rejection, a xenograft model was chosen. Mouse cornea from 12 mice of either sex were used as donor tissues for rat. [00062] Eighteen rats of either sex were used in the study. They were divided into 3 groups. Group #1 - 6 animals received treatment with the dexamethasone implant, Group #2 - received treatment with topical steroid and Group #3 - control group (without any treatment). Animals were followed up to 8 weeks. After euthanasia eyes were sent for histopathology examination. [00063] Table 1. Study design
Animal # Group # Eye Treatment
1 1 OD Dex implant
2 1 "
3 1 " 4 1
5 1
6 1
7 2 Dex eye drops
8 2
9 2
10 2
11 2
12 2
13 3 Control (no treatment)
14 3
15 3
16 3
17 3
18 3
[00064] S Suupppplliieess:: 0.5% Ophthaine Solution, euthasol solution, ketamine HC1, xylazine
ANIMAL PREPARATION AND SURGICAL PROCEDURE
[00065] Obtaining donor corneas: Each mouse was weighed and anesthetized.
While under anesthesia, the ophthalmologist collected all donor cornea buttons from mice using trephine. After the procedure mice were euthanized by a lethal dose of Euthasol.
[00066] Penetrating keratoplasty (PKP): Each rat was weighed and anesthetized.
Using 2.5 mm trephine an initial incision was made in the middle of cornea. The incision was finished using corneal scissors. The anterior chamber (AC) was held using balanced salt solution (BSS). The donor cornea button was attached to the host cornea with
8 interrupted sutures with 11-0 nylon. Before closing the anterior chamber, the dexamethasone implant was implanted into the AC of the first 6 animals.
[00067] All eighteen rats survived the procedure. All eyes were examined by an ophthalmologist by slit lamp and all signs of cornea rejection (neovascularization, edema, etc.) were recorded.
[00068] In group #2, all animals received 2 drops of Dexamethasone eye drops every day, until the rejection occurred.
[00069] Based on clinical observation, rejection of cornea in Group #3 (control) occurred in the first few days after surgery, and by week one 80% of donors' cornea were rejected, by week two 100%. Corneas were showing heavy neovascularization in the first few days followed by corneal edema and total rejection. Group #2 (topical Dexamethasone eye drops) had similar signs observed in this group with some delay. 20% of cornea rejection occurred by week two, 50% by week three, and 80% by week six. At the time of euthanasia (week 8) only 20% were not completely rejected.
[00070] However, in group #1, treated with the dexamethasone implant, the corneas did not show any signs of rejection (neovascularization, edema). In all eyes the corneas stayed clear. By the end of the study (week eight) the graft survival was 100%. [00071] Histopathology examination confirmed the clinical observations. In
Group #3 heavy inflammation was observed in AC, cornea endothelium, also in the stroma, and some in the epithelium. Corneas also showed edema due to destroyed endothelial cells. [00072] In Group #2 similar findings were observed.
[00073] In Group #1, inflammation was totally suppressed by the dexamethasone implant.
[00074] The entire clinical and histological finding in this study clearly demonstrated that intraocular sustained release Dexamethasone can prevent corneal rejection in a high- risk xenograft model.
Example 2: Manufacture And In vitro Testing Of Bioerodible Dexamethasone Posterior Segment Drug Delivery System fDEX PS DPS®)
[00075] 2100 mg of dexamethasone powder (Upjohn) (particle sizes less than 10 μm in diameter) were mixed with 900 mg of 50/50 polylactic acid polyglycolic acid (PLGA) (particle sizes approximately 9-12 μm in diameter) at ambient temperature. A small Teflon® tube was filled with 900-1100 μg of the above mixture, and placed directly on the die cavity. The powder was pushed out of the tubing into the die cavity with a stainless steel wire and the tube and wire were removed from the die. The powder was pressed using a tablet press (approximately 76 psi), ejected with the ejector switch, and removed with tweezers. The resulting pellet was approximately 2mm x 0.75mm. [00076] Release of dexamethasone from the DEX PS DDS® system was measured.
One DDS was placed in a glass vial filled with receptor medium (0.9% NaCl in water). To allow for "infinite sink" conditions, the receptor medium volume was chosen so that the concentration would never exceed 5% of saturation. To minimize secondary transport phenomena, e.g. concentration polarization in the stagnant boundary layer, the glass vial was placed into a shaking water bath at 37°C. Samples were taken for HPLC analysis from the vial at defined time points. The HPLC method was as described in USP 23(1995) pp.1791 -1798. The concentration values were used to calculate the cumulative release data, as shown in Table 2.
Table 2. DEX PS DDS® In vitro Release
Day % Total Release
1 10.1
2 16.4
7 39.4
14 55.5
21 69.3
28 80.7
35 88.1
[00077] Table 2 shows an almost linear in vitro release of dexamethasone over a one month period of time.
Example 3: In vivo Testing Of DEX PS DDS® In Rabbits
[00078] One DEX PS DDS® per eye was implanted into the vitreous of four rabbits with forceps. The in vivo vitreous concentrations of dexamethasone in each of the four eyes were monitored by vitreous sampling. For example, at day 2 the concentrations measured were 0.03 μg/ml, 0.1 μg/ml, 0.33 μg/ml and 0.19 μg/ml. The concentrations in each of the four eyes were measured on days 2, 7, 21, 28 and 35; the average results are summarized in Table 3. The volume of rabbit eyes is approximately 60-70% percent that of human eyes. Table 3. In vivo concentrations of dexamethasone (DDS placed with forceps)
Day μg/ml
2 0.16 ± 0.13
7 0.15 + 0.16
21 0.08 ± 0.07
28 0.005 + 0.01
35 0.037 + 0.03
[00079] The same DDS was tested in vivo in rabbits, wherein the DDS was placed to a depth of about 5-10 mm in the vitreous with trocar. The levels of dexamethasone in the vitreous are shown in Table 4.
Figure imgf000021_0001
DDS wt. Dex wt. Dex μg/mL
Animal#\day μg μg 2 7 14 21 28 35
21427-D 990 693 2.29
21427-S 1023 715.1 1.56
21433-D 804 562.8 1.2
21433-S 1057 739.9 0.77
21428-D 1003 702.1 9.26
21428-S 1025 717.5 0.35
21434-D 863 604.1 3.31 21434-S 1106 774.2 0.84
21429-D 1013 709.1 n/a
21429-S 927 648.9 0.19
21435-D 1104 772.8 0.43
21435-S 941 658.7 ^ 0.11
21432-D 860 692 0.43
21432-S 941 685.7 1.72
21436-D 1010 707 0.31
21436-S 1054 737.8 0.13
21431-D 996 697.2 0.52
21431-S 918 642.6 1.15
21437-D 1049 732.9 0.19
21437-D 1075 752.5 0.48
21430-D 994 695.8 0.06
21430-S 1086 760.2 0.18
21438-D 974 681.8 0.03
21438-S 831 581.7 8.35
Ave. 985.17 694.43 1.46 3.44 0.24 0.65 0.59 2.16
* Unable to determine due to insufficient sample
[00080] The data indicate that the DEX PS DDS® releases dexamethasone to the vitreous in concentrations above 0.01 μg/ml for an extended period of time. Further, the data indicate that placement of the device with trocar results in much higher levels of drug release than with placement with forceps, most likely due to placement of the device deeper within the vitreous. The data at two, four, six, and 24 hours in Table 4 shows an initial spike of drug release.
Example 4: Manufacture And In vitro Testing Of 50/50 Dexamethasone PLGA Posterior Segment Drug Delivery System
[00081] 2.5 g of PLGA (particle sizes approximately 9-12 μm in diameter) were placed in a mixing vessel. The vessel was placed in the oven (130°C) for ten minutes. 2.5 g of dexamethasone (particle sizes less than approximately 10 μm in diameter) were added to the vessel, and the vessel was returned to the oven for 10 minutes. The PLGA/dexamethasone mixture was mixed well, the blend loaded into a barrel, and 650-790 μm diameter filaments extruded. The resulting filaments were cut into lengths of approximately 0.94 and 1.87 mm for the 500 μg and 1000 μg formulations, respectively. [00082] Release of dexamethasone from the 50/50 dexamethasone/PLGA DDS formulations were measured. One DDS was placed in a glass vial filled with receptor medium (0.9% NaCl in water). To allow for "infinite sink" conditions, the receptor medium volume was chosen so that the concentration would never exceed 5% of saturation. To minimize secondary transport phenomena, e.g. concentration polarization in the stagnant boundary layer, the glass vial was placed into a shaking water bath at 37°C. Samples were taken for HPLC analysis from the vial at defined time points. The HPLC method was as described in USP 23(1995) pp.1791-1798. The concentration values were used to calculate the cumulative release data, as shown in Tables 5 and 6.
Table 5. In vitro release of 50% Dex-PS (0.5 mg formulation) 50% Dex PS 0.5 mg system replicate 1
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000024_0002
Table 6. In vitro release of 50% Dex-PS (1 mg formulation)
50% Dex PS 1 mg system replicate 1
Figure imgf000025_0001
Figure imgf000025_0002
Figure imgf000026_0001
Example 5: In vivo Testing Of 50/50 Dexamethasone/PLGA 1 mg Formulations
In Rabbits
[00083] One 50/50 dexamethasone/PLGA 1 mg formulation DDS per eye was implanted into the vitreous of 6 rabbits using a trocar. The DDS was loaded into the trocar, a hole was punched through the sclera, the trocar inserted through the hole, and the trocar plunger depressed to insert the DDS into the vitreous. In vivo vitreous concentrations of dexamethasone were monitored, as shown in Table 7.
Table 7. In vivo vitreous concentrations of dexamethasone
Figure imgf000026_0002
Figure imgf000027_0001
Figure imgf000027_0002
* High level was due to the surgical artifact
[00084] The data indicate that the 50/50 dexamethasone/PLGA DDS releases dexamethasone to the vitreous in concentrations above 0.01 μg/ml for an extended period of time. The data at two, four, six, and 24 hours in Table 7 shows an initial spike of drug release, due to drug which is unencapsulated by the delivery system. [00085] Modifications of the above described modes for carrying out the invention that are obvious to those of ordinary skill in the surgical, pharmaceutical, or related arts are intended to be within the scope of the following claims.

Claims

Claims
1. The use of an immunosuppressive agent and a bioerodible polymer in the manufacture of a bioerodible drug delivery system for use in a method for reducing or preventing transplant rejection in an eye of an individual, wherein the method comprises
a) performing an ocular transplant procedure on an eye of an individual; and b) placing in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
2. The method of claim 1 , wherein the ocular transplant procedure is a retinal pigment epithelium (RPE) transplant or a cornea transplant.
3. The method of claim 2, wherein the ocular transplant procedure is an RPE transplant.
4. The method of claim 2, wherein the ocular transplant procedure is a cornea transplant.
5. The method of claim 1, wherein the bioerodible drug delivery system is placed in the anterior chamber of the eye.
6. The method of claim 1, wherein the bioerodible drug delivery system is placed in the vitreous cavity of the eye.
7. The method of claim 1, wherein the immunosuppressive agent is selected from the group consisting of dexamethasone, cyclosporin A, azathioprine, brequinar, gusperimus, 6-mercaptopurine, mizoribine, rapamycin, tacrolimus (FK-506), denopterin, edatrexate, methotrexate, piritrexim, pteropterin, Tomudex®, trimetrexate, cladribine, fludarabine, 6-mercaptopurine, thiamiprine, thiaguanine, ancitabine, azacitidine, 6- azauridine, carmofur, cytarabine, doxifluridine, emitefur, enocitabine, floxuridine, fluorouracil, gemcitabine, egafur, fluocinolone, triaminolone, anecortave acetate, fluorometholone, medrysone, and prednislone.
8. The method of claim 7, wherein the immunosuppressive agent is dexamethasone.
9. The method of claim 8, wherein the bioerodible drug delivery system comprises about 50% by weight of dexamethasone, about 15% by weight of hydroxypropyl methylcellulose (HPMC) and about 35% by weight of polylactic polyglycolic acid (PLGA).
10. The method of claim 8, wherein the bioerodible drug delivery system comprises about 60% by weight of dexamethasone and about 40% by weight of polylactic polyglycolic acid (PLGA).
11. The method of claim 8, wherein the bioerodible drug delivery system comprises about 50% by weight of dexamethasone and about 50% by weight of polylactic polyglycolic acid (PLGA).
12. The method of claim 7, wherein the immunosuppressive agent is cyclosporin A.
13. The method of claim 1, wherein the bioerodible polymer is a polyester.
14. The method of claim 1, wherein the bioerodible polymer is a polylactic acid polyglycolic acid (PLGA) copolymer.
15. The method of claim 14, wherein the implant further comprises hydroxy propyl methyl cellulose (HPMC).
16. The method of claim 1, wherein the individual is a human.
17. The use of an immunosuppressive agent and a bioerodible polymer in the manufacture of a bioerodible drug delivery system for use in a method for preventing transplant rejection in the eye of an individual, wherein the method comprises: a) performing an ocular transplant procedure; and b) implanting a solid body into the eye; wherein the solid body comprises particles of an immunosuppressive agent entrapped within a bioerodible polymer; and whereby the immunosuppressive agent is released from the solid body by erosion of the bioerodible polymer.
18. The use of dexamethasone or cyclosporin A and a bioerodible polymer in the manufacture of a bioerodible drug delivery system for use in a method comprising a) performing a retinal pigment epithelium transplant or a cornea transplant on an eye of an individual; and b) placing in the eye a bioerodible drug delivery system comprising dexamethasone or cyclosporin A and a bioerodible polymer.
19. The method of claim 18, wherein the bioerodible drug delivery system is placed in an anterior chamber of the eye.
20. The method of claim 18, wherein the bioerodible drug delivery system is placed in a vitreous cavity of the eye.
21. The method of claim 18, wherein the bioerodible drug delivery system comprises about 50% by weight of dexamethasone or cyclosporin A, about 15% by weight of hydroxypropyl methylcellulose (HPMC), and about 35% by weight of polylactic polyglycolic acid (PLGA).
22. The method of claim 18, wherein the bioerodible drug delivery system comprises about 60% by weight of dexamethasone or cyclosporin A and about 40% by weight of polylactic polyglycolic acid (PLGA).
23. The method of claim 18, wherein the bioerodible drug delivery system comprises about 50% by weight of dexamethasone or cyclosporin A and about 50% by weight of polylactic polyglycolic acid (PLGA).
24. The method of claim 18, wherein the bioerodible polymer is a polyester.
25. The method of claim 18, wherein the bioerodible polymer is a polylactic acid polyglycolic acid (PLGA) copolymer.
26. The method of claim 25, wherein the implant further comprises hydroxy propyl methyl cellulose (HPMC).
27. The method of claim 18, wherein the individual is a human.
28. The use of an immunosuppressive agent and a bioerodible polymer in the manufacture of a bioerodible drug delivery system for use in a method comprising placing in an eye of an individual a bioerodible drug delivery system; wherein the bioerodible drug delivery system includes an immunosuppressive agent and a bioerodible polymer; and wherein the eye of the individual has undergone or is undergoing an ocular transplant procedure.
29. The method of claim 28, wherein the ocular transplant procedure is a retinal pigment epithelium (RPE) transplant or a cornea transplant.
30. The method of claim 29, wherein the ocular transplant procedure is an RPE transplant.
31. The method of claim 29, wherein the ocular transplant procedure is a cornea transplant.
32. The method of claim 28, wherein the bioerodible drug delivery system is placed in the anterior chamber of the eye.
33. The method of claim 28, wherein the bioerodible drug delivery system is placed in the vitreous cavity of the eye.
34. The method of claim 28, wherein the immunosuppressive agent is selected from the group consisting of dexamethasone, cyclosporin A, azathioprine, brequinar, gusperimus, 6-mercaptopurine, mizoribine, rapamycin, tacrolimus (FK-506), denopterin, edatrexate, methotrexate, piritrexim, pteropterin, Tomudex®, trimetrexate, cladribine, fludarabine, 6-mercaptopurine, thiamiprine, thiaguanine, ancitabine, azacitidine, 6- azauridine, carmofur, cytarabine, doxifluridine, emitefur, enocitabine, floxuridine, fluorouracil, gemcitabine, egafur, fluocinolone, triaminolone, anecortave acetate, fluorometholone, medrysone, and prednislone.
35. The method of claim 34, wherein the immunosuppressive agent is dexamethasone.
36. The method of claim 35, wherein the bioerodible drug delivery system comprises about 50% by weight of dexamethasone, about 15% by weight of hydroxypropyl methylcellulose (HPMC) and about 35% by weight of polylactic polyglycolic acid (PLGA).
37. The method of claim 35, wherein the bioerodible drug delivery system comprises about 60% by weight of dexamethasone and about 40% by weight of polylactic polyglycolic acid (PLGA).
38. The method of claim 35, wherein the bioerodible drug delivery system comprises about 50%) by weight of dexamethasone and about 50% by weight of polylactic polyglycolic acid (PLGA).
39. The method of claim 34, wherein the immunosuppressive agent is cyclosporin A.
40. The method of claim 28, wherein the bioerodible polymer is a polyester.
41. The method of claim 28, wherein the bioerodible polymer is a polylactic acid polyglycolic acid (PLGA) copolymer.
42. The method of claim 41, wherein the implant further comprises hydroxy propyl methyl cellulose (HPMC).
43. The method of claim 28, wherein the individual is a human.
44. A kit, comprising: a) a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer, wherein the drug delivery system is designed to be implanted in the eye; and b) instructions for use.
45. The kit of claim 44, wherein the immunosuppressive agent is dexamethasone.
PCT/US2001/044481 2000-11-29 2001-11-28 Intraocular implants for preventing transplant rejection in the eye WO2002043785A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DE60114229T DE60114229T2 (en) 2000-11-29 2001-11-28 PREVENTING TRANSPLANT DISCHARGE IN THE EYE
BR0115772-8A BR0115772A (en) 2000-11-29 2001-11-28 Processes for reducing or preventing eye transplant rejection and intraocular implants for use in transplantation
AU2002236495A AU2002236495B2 (en) 2000-11-29 2001-11-28 Intraocular implants for preventing transplant rejection in the eye
AU3649502A AU3649502A (en) 2000-11-29 2001-11-28 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
JP2002545755A JP2004514702A (en) 2000-11-29 2001-11-28 Intraocular implant for preventing transplant rejection in the eye
CA2429998A CA2429998C (en) 2000-11-29 2001-11-28 Intraocular implants for preventing transplant rejection in the eye
EP01986027A EP1339438B1 (en) 2000-11-29 2001-11-28 Preventing transplant rejection in the eye
AT01986027T ATE306951T1 (en) 2000-11-29 2001-11-28 PREVENTING TRANSPLANT REJECTION IN THE EYE
AU2006201271A AU2006201271B2 (en) 2000-11-29 2006-03-28 Intraocular implants for preventing transplant rejection in the eye

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25002300P 2000-11-29 2000-11-29
US60/250,023 2000-11-29
US29825301P 2001-06-12 2001-06-12
US60/298,253 2001-06-12

Publications (2)

Publication Number Publication Date
WO2002043785A2 true WO2002043785A2 (en) 2002-06-06
WO2002043785A3 WO2002043785A3 (en) 2002-11-21

Family

ID=26940539

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/044481 WO2002043785A2 (en) 2000-11-29 2001-11-28 Intraocular implants for preventing transplant rejection in the eye

Country Status (11)

Country Link
US (16) US6699493B2 (en)
EP (1) EP1339438B1 (en)
JP (3) JP2004514702A (en)
AT (1) ATE306951T1 (en)
AU (3) AU2002236495B2 (en)
BR (1) BR0115772A (en)
CA (1) CA2429998C (en)
DE (1) DE60114229T2 (en)
DK (1) DK1339438T3 (en)
ES (1) ES2250504T3 (en)
WO (1) WO2002043785A2 (en)

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107718A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Anti-excitotoxic sustained release intraocular implants and related methods
WO2005110362A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Biodegradable ocular implants with long-term release characteristics
WO2005110366A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. An estradiol derivative or an estratopone derivative containing sustained release intraocular implant as well as related methods of manufacturing
WO2006036280A1 (en) * 2004-08-13 2006-04-06 Allergan, Inc. Ocular implant made by a double extrusion process
EP1740193A2 (en) * 2004-04-30 2007-01-10 Allergan, Inc. Macromolecule-containing sustained release intraocular implants and related methods
JP2007526226A (en) * 2003-06-16 2007-09-13 ボシュ・アンド・ロム・インコーポレイテッド Rate-controlled release of pharmaceuticals in biodegradable devices
WO2007109530A1 (en) * 2006-03-20 2007-09-27 Allergan, Inc. Cyclosporin a compositions
JP2007535566A (en) * 2004-04-30 2007-12-06 アラーガン、インコーポレイテッド Steroid intraocular implant that provides long-term sustained release for more than 2 months
JP2007535540A (en) * 2004-04-30 2007-12-06 アラーガン、インコーポレイテッド Intravitreal implants combined with photodynamic therapy to improve vision
WO2008093086A1 (en) 2007-01-31 2008-08-07 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses
EP1944032A3 (en) * 2004-04-30 2010-10-06 Allergan, Inc. Biodegradable intraocular implants containing prostamides
EP2278978A2 (en) * 2008-05-28 2011-02-02 Validus Biopharma, Inc. Non-hormonal steroid modulators of nf-kb for treatment of disease
EP1917957A3 (en) * 2003-01-09 2011-06-15 Allergan, Inc. Biodegradable ocular implant
WO2012003210A1 (en) * 2010-06-30 2012-01-05 Surmodics Pharmaceuticals, Inc. Implant processing methods for thermally labile and other bioactive agents and implants prepared from same
US8529927B2 (en) 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US8647659B2 (en) 2010-01-22 2014-02-11 Allergan, Inc. Intracameral sustained release therapeutic agent implants
AU2012216644B2 (en) * 2004-08-13 2014-04-10 Allergan, Inc. Ocular implant made by a double extrusion process
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
JP2014156496A (en) * 2004-04-30 2014-08-28 Allergan Inc Method for producing preparation of biodegradable microspheres
US9089478B2 (en) 2003-11-12 2015-07-28 Allergen, Inc. Peripherally administered viscous formulations
US9198921B2 (en) 2010-04-05 2015-12-01 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
US9233070B2 (en) 2004-04-30 2016-01-12 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
WO2016079204A1 (en) 2014-11-18 2016-05-26 Pierre Coulon Multifunctional capsular implant
AU2014201844B2 (en) * 2004-08-13 2016-06-16 Allergan, Inc Ocular implant made by a double extrusion process
WO2016191820A1 (en) * 2015-06-02 2016-12-08 Newsouth Innovations Pty Limited Formulation and process for limiting nerve trauma
US9610246B2 (en) 2013-02-15 2017-04-04 Allergan, Inc. Sustained drug delivery implant
US9669039B2 (en) 2004-04-30 2017-06-06 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US9775849B2 (en) 2000-07-05 2017-10-03 Allergan, Inc. Implants and methods for treating inflammation-mediated conditions of the eye
US9775846B2 (en) 2004-04-30 2017-10-03 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related implants
US9980974B2 (en) 2013-10-31 2018-05-29 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
AU2016228285B2 (en) * 2004-08-13 2018-06-28 Allergan, Inc. Ocular implant made by a double extrusion process
US10201641B2 (en) 2004-04-30 2019-02-12 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US10406029B2 (en) 2001-04-07 2019-09-10 Glaukos Corporation Ocular system with anchoring implant and therapeutic agent
US10669383B2 (en) 2006-10-31 2020-06-02 Evonik Corporation Spheronized polymer particles
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
US10959941B2 (en) 2014-05-29 2021-03-30 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US11253394B2 (en) 2013-03-15 2022-02-22 Dose Medical Corporation Controlled drug delivery ocular implants and methods of using same
US11318043B2 (en) 2016-04-20 2022-05-03 Dose Medical Corporation Bioresorbable ocular drug delivery device
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
DK1339438T3 (en) 2000-11-29 2006-02-13 Allergan Inc Prevention of transplant rejection in the eye
US20020082678A1 (en) * 2000-12-22 2002-06-27 Motasim Sirhan Intravascular delivery of mizoribine
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US7090888B2 (en) * 2002-01-18 2006-08-15 Snyder Michael E Sustained release ophthalmological device and method of making and using the same
US20030180294A1 (en) * 2002-02-22 2003-09-25 Devries Gerald W. Methods of extending corneal graft survival
DK1539157T3 (en) * 2002-09-18 2013-10-07 Univ Pennsylvania METHOD OF INHALING CHOROIDAL NEOVASCULARIZATION
AU2003279055A1 (en) * 2002-09-29 2004-04-19 Surmodics, Inc. Methods for treatment and/or prevention of retinal disease
US20050037047A1 (en) * 2003-08-11 2005-02-17 Young-Ho Song Medical devices comprising spray dried microparticles
US7060723B2 (en) 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
US7125908B2 (en) * 2003-08-29 2006-10-24 Allergan, Inc. Treating pain using selective antagonists of persistent sodium current
US7585517B2 (en) * 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
EP1711196A4 (en) 2003-12-05 2011-09-14 Bristol Myers Squibb Co Inhibitors of type 2 vascular endothelial growth factor receptors
US7976520B2 (en) * 2004-01-12 2011-07-12 Nulens Ltd. Eye wall anchored fixtures
CA2553381C (en) 2004-01-20 2011-03-22 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
EP2438815A3 (en) 2004-01-23 2012-10-03 Advanced Cell Technology, Inc. Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US7589057B2 (en) 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US20050244458A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
EP1751612B1 (en) * 2004-05-06 2009-02-25 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Methods and compositions for the treatment of uveitis
US8372814B2 (en) 2004-06-07 2013-02-12 Ista Pharmaceuticals, Inc. Ophthalmic formulations and uses thereof
US8748402B2 (en) 2004-06-07 2014-06-10 Bausch & Lomb Pharma Holdings Corp. Ophthalmic formulations and uses thereof
US20060024350A1 (en) * 2004-06-24 2006-02-02 Varner Signe E Biodegradable ocular devices, methods and systems
US20060110428A1 (en) * 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
EP2216026B1 (en) * 2004-07-12 2016-04-20 Allergan, Inc. Ophthalmic compositions and uses for treating ophthalmic conditions
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
KR101506925B1 (en) * 2004-10-01 2015-03-30 램스코르 인코포레이티드 Conveniently implantable sustained release drug compositions
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US8246949B2 (en) * 2004-10-27 2012-08-21 Aciont, Inc. Methods and devices for sustained in-vivo release of an active agent
WO2006086750A1 (en) * 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US20060204548A1 (en) * 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
US20060233858A1 (en) * 2005-03-08 2006-10-19 Allergan, Inc. Systems and methods providing targeted intraocular drug delivery
CA2602525A1 (en) * 2005-03-21 2006-09-28 Macusight, Inc. Drug delivery systems for treatment of diseases or conditions
EP1868661A1 (en) 2005-04-08 2007-12-26 SurModics, Inc. Sustained release implants for subretinal delivery
US7931909B2 (en) * 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
EP1924292A2 (en) * 2005-09-16 2008-05-28 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
CN101394834A (en) * 2005-10-18 2009-03-25 阿勒根公司 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
EP1971342A1 (en) * 2005-12-15 2008-09-24 ActivBiotics Pharma LLC Uses of rifamycins
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
BRPI0707446A2 (en) 2006-02-02 2011-05-03 Allergan Inc compositions and methods for the treatment of ophthalmic disease
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
US20070212420A1 (en) * 2006-03-10 2007-09-13 Bausch & Lomb Incorporated Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives
KR101520408B1 (en) 2006-03-23 2015-05-14 산텐 세이야꾸 가부시키가이샤 Formulations and methods for vascular permeability-related diseases or conditions
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US7981096B2 (en) * 2006-05-12 2011-07-19 David Castillejos Optic nerve head implant and medication delivery system
US7687484B2 (en) * 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
US8668676B2 (en) * 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US9039761B2 (en) 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
CL2007002958A1 (en) * 2006-10-12 2008-05-09 Epix Delaware Inc COMPOUNDS DERIVED FROM HETEROARIL-CARBOXAMIDA, ANTAGONISTS OF THE CHEMIOQUINE RECEPTOR; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OR PREVENTION OF SUCH DISEASES AS REJECTION OF ORGAN TRANSPLANTS, Rheumatoid Arthritis, LUPUS, ENTR
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8586556B2 (en) * 2006-11-03 2013-11-19 Allergan, Inc. Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
US20080114076A1 (en) * 2006-11-09 2008-05-15 Alcon Manufacturing Ltd. Punctal plug comprising a water-insoluble polymeric matrix
TWI409081B (en) * 2006-11-09 2013-09-21 Alcon Res Ltd Water insoluble polymer matrix for drug delivery
MX2009005466A (en) 2006-11-22 2009-08-17 Adnexus A Bristol Myers Sqibb Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir.
EP2091482A2 (en) 2006-12-01 2009-08-26 Allergan, Inc. Method for determining optimum intraocular locations for drug delivery systems
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US8536190B2 (en) * 2007-01-30 2013-09-17 Allergan, Inc. Treating unwanted ocular conditions using an ascomycin macrolactam
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US20090148498A1 (en) * 2007-05-14 2009-06-11 Sustained Nano Systems Llc Controlled release implantable dispensing device and method
CA2701482C (en) 2007-10-08 2018-10-23 Lux Biosciences, Inc. Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors
CN101878295A (en) 2007-10-12 2010-11-03 先进细胞技术公司 Improved methods of producing RPE cells and compositions of RPE cells
US20090104240A1 (en) * 2007-10-19 2009-04-23 Abbott Cardiovascular Systems Inc. Dual Drug Formulations For Implantable Medical Devices For Treatment of Vascular Diseases
JP2011506466A (en) 2007-12-11 2011-03-03 株式会社サイトパスファインダー Carboxamide compounds and their use as chemokine receptor agonists
US20090196905A1 (en) * 2008-02-06 2009-08-06 Spada Lon T Stabilization of mitochondrial membranes in ocular diseases and conditions
JP2011517314A (en) 2008-02-14 2011-06-02 ブリストル−マイヤーズ スクイブ カンパニー Targeted therapeutics based on engineered proteins that bind to EGFR
US10588855B2 (en) 2008-05-12 2020-03-17 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
CN102026599A (en) 2008-05-12 2011-04-20 犹他大学研究基金会 Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
WO2009142773A2 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
US9642658B2 (en) 2008-10-15 2017-05-09 Orthoclip Llc Device and method for delivery of therapeutic agents via internal implants
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US8034813B2 (en) 2008-11-18 2011-10-11 Bausch & Lomb Incorporated Polymorphs of brimonidine pamoate
TWI496582B (en) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 Bispecific egfr/igfir binding molecules
US8545554B2 (en) * 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
US20100291182A1 (en) * 2009-01-21 2010-11-18 Arsenal Medical, Inc. Drug-Loaded Fibers
US8409606B2 (en) 2009-02-12 2013-04-02 Incept, Llc Drug delivery through hydrogel plugs
WO2010093945A2 (en) 2009-02-13 2010-08-19 Glaukos Corporation Uveoscleral drug delivery implant and methods for implanting the same
AU2010259184B2 (en) 2009-06-09 2015-08-13 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
CA2767260A1 (en) * 2009-07-09 2011-01-13 Dsm Ip Assets B.V. Solid linear oligo-or poly-.epsilon.-caprolactone derivatives
US20110202016A1 (en) * 2009-08-24 2011-08-18 Arsenal Medical, Inc. Systems and methods relating to polymer foams
US9173817B2 (en) 2009-08-24 2015-11-03 Arsenal Medical, Inc. In situ forming hemostatic foam implants
US9044580B2 (en) 2009-08-24 2015-06-02 Arsenal Medical, Inc. In-situ forming foams with outer layer
US10420862B2 (en) 2009-08-24 2019-09-24 Aresenal AAA, LLC. In-situ forming foams for treatment of aneurysms
CN102724951A (en) 2009-11-09 2012-10-10 阿勒根公司 Compositions and methods for stimulating hair growth
IL281453B (en) 2009-11-17 2022-07-01 Astellas Inst For Regenerative Medicine Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
WO2011097634A1 (en) 2010-02-08 2011-08-11 On Demand Therapeutics, Inc. Low-permeability, laser-activated drug delivery device
JP2013526572A (en) 2010-05-17 2013-06-24 アエリエ・ファーマシューティカルズ・インコーポレーテッド Drug delivery device for the delivery of eye treatments
ES2573108T3 (en) 2010-05-26 2016-06-06 Bristol-Myers Squibb Company Fibronectin-based framework proteins that have improved stability
CA2806127C (en) 2010-07-23 2021-12-21 Advanced Cell Technology, Inc. Methods for detection of rare subpopulations of cells and highly purified compositions of cells
WO2012056201A2 (en) 2010-10-27 2012-05-03 Hovione Inter Limited Electrophilic reagents for monohalomethylation,their preparation and their uses
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
US9194058B2 (en) 2011-01-31 2015-11-24 Arsenal Medical, Inc. Electrospinning process for manufacture of multi-layered structures
US8968626B2 (en) 2011-01-31 2015-03-03 Arsenal Medical, Inc. Electrospinning process for manufacture of multi-layered structures
US9034240B2 (en) 2011-01-31 2015-05-19 Arsenal Medical, Inc. Electrospinning process for fiber manufacture
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
WO2013023115A1 (en) 2011-08-10 2013-02-14 On Demand Therapeutics, Inc. Laser-activated drug delivery device
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
US8993831B2 (en) 2011-11-01 2015-03-31 Arsenal Medical, Inc. Foam and delivery system for treatment of postpartum hemorrhage
TW202317157A (en) 2011-11-14 2023-05-01 安斯泰來再生醫藥協會 Pharmaceutical preparations of human rpe cells and uses thereof
EP3613413A1 (en) 2011-12-05 2020-02-26 Incept, LLC Medical organogel processes and compositions
US8945214B2 (en) 2011-12-19 2015-02-03 Allergan, Inc. Intravitreal applicator
WO2013119843A1 (en) 2012-02-07 2013-08-15 On Demand Therapeutics, Inc. Drug delivery devices and methods of use thereof
US10405961B2 (en) 2013-03-14 2019-09-10 Cell and Molecular Tissue Engineering, LLC Coated surgical mesh, and corresponding systems and methods
US10130288B2 (en) 2013-03-14 2018-11-20 Cell and Molecular Tissue Engineering, LLC Coated sensors, and corresponding systems and methods
JP6340673B2 (en) 2013-05-02 2018-06-13 レティナ ファウンデーション オブ ザ サウスウエストRetina Foundation Of The Southwest Double-layered ocular implant
JP6543431B2 (en) * 2013-10-10 2019-07-10 ユニバーシティー オブ ユタ リサーチ ファウンデーションUniversity of Utah Research Foundation Intraocular drug delivery device and associated method
WO2015073651A1 (en) 2013-11-13 2015-05-21 Brooks Automation, Inc. Method and apparatus for brushless electrical machine control
RU2690841C1 (en) 2013-11-15 2019-06-06 Аллерган, Инк. Methods for treating pathology of eye by means of implant with durable delivery of drug subjects
WO2017053686A1 (en) * 2015-09-24 2017-03-30 Massachusetts Eye And Ear Infirmary Drug delivery system and methods of use
US10883108B2 (en) 2016-03-31 2021-01-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
US11337968B2 (en) * 2016-04-29 2022-05-24 The Board Of Regents Of The University Of Oklahoma Phenylquinoline compositions for treatment of ocular disorders and conditions
AU2017312499B2 (en) 2016-08-19 2023-02-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration
US11229662B2 (en) 2016-11-15 2022-01-25 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
ES2945740T3 (en) 2017-05-05 2023-07-06 Univ Pittsburgh Commonwealth Sys Higher Education Matrix-Bound Vesicles (MBV) Ocular Applications
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US11260048B2 (en) 2017-10-03 2022-03-01 The Schepens Eye Research Institute, Inc. Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
WO2019099560A1 (en) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
EP3758736A1 (en) 2018-03-02 2021-01-06 The United States of America, as represented by the Secretary, Department of Health and Human Services Use of il-34 to treat retinal inflammation and neurodegeneration
US10351602B1 (en) 2018-05-31 2019-07-16 University Of South Florida Antimicrobial analogues of gramicidin S
AU2020302924A1 (en) 2019-06-27 2022-02-17 Layerbio, Inc. Ocular device delivery methods and systems
US20230066585A1 (en) 2020-01-17 2023-03-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Gene therapy for treatment of crx-autosomal dominant retinopathies
WO2023105417A1 (en) 2021-12-06 2023-06-15 Breye Therapeutics Aps Danegaptide formulation for applicatoin in the eye

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037056A2 (en) * 1998-12-23 2000-06-29 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma

Family Cites Families (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE636865A (en) 1962-08-31
US3416530A (en) 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3986510A (en) 1971-09-09 1976-10-19 Alza Corporation Bioerodible ocular device
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3914402A (en) 1973-06-14 1975-10-21 Alza Corp Ophthalmic dosage form, for releasing medication over time
SE390255B (en) 1974-02-18 1976-12-13 N G Y Torphammar RELEASE DEVICE PREFERRED FOR A SAFETY BELT IN A VEHICLE
US3961628A (en) * 1974-04-10 1976-06-08 Alza Corporation Ocular drug dispensing system
US3921632A (en) 1974-08-16 1975-11-25 Frank M Bardani Implant device
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4201210A (en) 1976-06-22 1980-05-06 The United States Of America As Represented By The Secretary Of Agriculture Veterinary ocular ring device for sustained drug release
US4186184A (en) 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4300557A (en) 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4402979A (en) 1980-03-21 1983-09-06 Merck & Co., Inc. & Laboratories Ophthalmic formulations of 5-fluoro-2-methyl-1-(p-methylthiobenzylidene)-3-indenylacetic acid
US4304765A (en) 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
EP0052916B1 (en) 1980-11-10 1985-01-02 Alza Corporation Erodible polymer containing erosion rate modifier
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS58126435U (en) 1982-02-19 1983-08-27 オリンパス光学工業株式会社 Aperture control circuit for TTL auto strobe
US4451254A (en) 1982-03-15 1984-05-29 Eli Lilly And Company Implant system
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
DE3220156C2 (en) 1982-05-28 1990-01-25 Heida Houston Tex. Thurlow Cooking and roasting utensils with lids provided with metal handles, in particular stainless steel handles
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
IT1229075B (en) 1985-04-05 1991-07-17 Fidia Farmaceutici Topical compsn. contg. hyaluronic acid deriv. as vehicle
US4478818A (en) 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US6217911B1 (en) 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4629621A (en) 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US5082655A (en) 1984-07-23 1992-01-21 Zetachron, Inc. Pharmaceutical composition for drugs subject to supercooling
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4966849A (en) 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
DE3612212A1 (en) 1986-04-11 1987-10-15 Basf Ag METHOD FOR PRODUCING SOLID PHARMACEUTICAL FORMS
US4756911A (en) 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5322691A (en) 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
US4863457A (en) * 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5006342A (en) 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
US5217895A (en) * 1987-02-19 1993-06-08 Nissin Shokuhin Kabushiki Kaisha Monoclonal anti-idiotypic antibodies specific for anti-T4 antibodies and cross-reactive with HIV
DE3734223A1 (en) 1987-10-09 1989-04-20 Boehringer Ingelheim Kg IMPLANTABLE, BIODEGRADABLE ACTIVE SUBSTANCE RELEASE SYSTEM
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4945089A (en) 1987-12-29 1990-07-31 Alcon Laboratories, Inc. Use of tetrahydrocortexolone to prevent elevations in intraocular pressure caused by corticosteroids
US4865846A (en) 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
GB8820353D0 (en) 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
ES2213504T1 (en) 1988-09-06 2004-09-01 Pfizer Health Ab PROSTAGLANDIN DERIVATIVES FOR THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION.
US5004601A (en) 1988-10-14 1991-04-02 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
SG49267A1 (en) 1989-08-14 1998-05-18 Photogenesis Inc Surgical instrument and cell isolation and transplantation
US5112614A (en) 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5268178A (en) 1989-09-25 1993-12-07 The Board Of Regents, The University Of Texas System Biodegradable antibiotic implants and methods of their use in treating and preventing infections
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5660851A (en) * 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
US5175235A (en) 1990-06-04 1992-12-29 Nova Pharmaceutical Corporation Branched polyanhydrides
US5075115A (en) 1990-04-02 1991-12-24 Fmc Corporation Process for polymerizing poly(lactic acid)
CA2078214C (en) 1990-04-02 1995-03-28 Robert Lee Dow Benzylphosphonic acid tyrosine kinase inhibitors
EP0474098B1 (en) 1990-08-30 1994-03-02 Senju Pharmaceutical Co., Ltd. Controlled drug release composition
KR0185215B1 (en) 1990-11-30 1999-05-01 요시다 쇼오지 A controlled-release pharmaceutical preparation for intra-ocular implant
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US6194439B1 (en) 1991-05-29 2001-02-27 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
WO1993000050A1 (en) 1991-06-21 1993-01-07 Genetics Institute, Inc. Pharmaceutical formulations of osteogenic proteins
US5356629A (en) 1991-07-12 1994-10-18 United States Surgical Corporation Composition for effecting bone repair
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
ATE232540T1 (en) 1991-11-22 2003-02-15 Alcon Lab Inc ANGIOSTATIC STEROIDS
US5543154A (en) 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
US6045791A (en) 1992-03-06 2000-04-04 Photogenesis, Inc. Retinal pigment epithelium transplantation
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5384333A (en) 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
SK283413B6 (en) 1992-08-06 2003-07-01 Warner-Lambert Company 2-Thioindoles, 2-indolinethiones and polysulfides, their analogues (2-indolineselenone) (selenide), and pharmaceutical compositions based on them
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
ATE215565T1 (en) 1992-10-28 2002-04-15 Genentech Inc USE OF ANTI-VEGF ANTIBODIES TO TREAT CANCER
US5314419A (en) 1992-10-30 1994-05-24 Pelling George E Method for dispensing ophthalmic drugs to the eye
ES2134860T3 (en) 1992-11-18 1999-10-16 Fujisawa Pharmaceutical Co PHARMACEUTICAL PREPARATION FOR PROLONGED ACTION.
DE4241045C1 (en) * 1992-12-05 1994-05-26 Bosch Gmbh Robert Process for anisotropic etching of silicon
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5538735A (en) 1993-02-19 1996-07-23 Ahn; Sam S. Method of making a drug delivery system using hollow fibers
WO1994018921A1 (en) 1993-02-26 1994-09-01 Santen Pharmaceutical Co., Ltd. Biodegradable sclera plug
US5707643A (en) 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
US5385887A (en) 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
DE4403326C1 (en) 1994-02-03 1995-06-22 Hans Reinhard Prof Dr Koch Intraocular lens arrangement for astigmatism correction
US5773021A (en) 1994-03-14 1998-06-30 Vetoquinol S.A. Bioadhesive ophthalmic insert
US5755785A (en) 1994-08-12 1998-05-26 The University Of South Florida Sutureless corneal transplantation method
US6063116A (en) 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
US6348208B1 (en) * 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5693335A (en) 1995-06-07 1997-12-02 Cygnus, Inc. Skin permeation enhancer composition for use with sex steroids
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
EP0817619A4 (en) 1996-01-24 1999-02-03 Us Army Novel "burst-free" sustained release poly-(lactide/glycolide) mi crospheres
US6046187A (en) 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
CA2272073A1 (en) 1996-11-19 1998-05-28 The Schepens Eye Research Institute, Inc. Local use of il-1ra in corneal transplant rejection or disorders of the eye
US5941250A (en) 1996-11-21 1999-08-24 University Of Louisville Research Foundation Inc. Retinal tissue implantation method
US20020111603A1 (en) 1996-12-02 2002-08-15 Societe De Conseils De Recherches Et D'application Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
EP0973499B1 (en) 1997-03-31 2003-08-06 Alza Corporation Diffusional implantable delivery system
CA2294714A1 (en) 1997-07-02 1999-01-14 Santen Pharmaceutical Co., Ltd. Polylactic acid scleral plugs
CA2300154C (en) * 1997-08-11 2008-07-08 Allergan Sales, Inc. Sterile bioerodible implant device with improved biocompatability and method
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6196993B1 (en) 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
KR20010071827A (en) 1998-07-10 2001-07-31 앤더슨 데릭 제이. Prophylactic treatments of neovascularisation in macular degeneration
US6406498B1 (en) 1998-09-04 2002-06-18 Bionx Implants Oy Bioactive, bioabsorbable surgical composite material
EP1130996B1 (en) * 1998-11-20 2005-04-13 The University of Connecticut Generic integrated implantable potentiostat telemetry unit for electrochemical sensors
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
AU7711800A (en) 1999-09-23 2001-04-24 Sloan-Kettering Institute For Cancer Research Novel uses of 2-bromopalmitate
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6375759B1 (en) * 1999-11-30 2002-04-23 Sandia Corporation Batch fabrication of precision miniature permanent magnets
US7335803B2 (en) 2001-10-19 2008-02-26 Allergan, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6545182B2 (en) 2000-04-13 2003-04-08 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US7708711B2 (en) 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US20040208910A1 (en) 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
US6478091B1 (en) 2000-05-04 2002-11-12 Halliburton Energy Services, Inc. Expandable liner and associated methods of regulating fluid flow in a well
US20040170665A1 (en) 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
DK1339438T3 (en) * 2000-11-29 2006-02-13 Allergan Inc Prevention of transplant rejection in the eye
EP1550471A1 (en) 2000-11-29 2005-07-06 Allergan Inc. Intraocular implants for preventing transplant rejection in the eye
US6534542B2 (en) 2001-02-27 2003-03-18 Allergen Sales, Inc. (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US7563255B2 (en) 2001-05-03 2009-07-21 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
CA2451187C (en) 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
US7282216B2 (en) 2001-11-12 2007-10-16 Alkermes Controlled Therapeutics, Inc. Biocompatible polymer blends and uses thereof
US6541504B1 (en) 2002-04-03 2003-04-01 Allergan Sales, Llc (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
MXPA04011004A (en) 2002-05-07 2005-01-25 Control Delivery Sys Inc Processes for forming a drug delivery device.
US7276522B2 (en) 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
JP3688287B1 (en) 2002-09-18 2005-08-24 アラーガン、インコーポレイテッド Device for delivering an ophthalmic implant
US7468065B2 (en) 2002-09-18 2008-12-23 Allergan, Inc. Apparatus for delivery of ocular implants
US6899717B2 (en) 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
CN1713890A (en) 2002-11-06 2005-12-28 阿尔萨公司 Controlled release depot formulations
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20040137059A1 (en) 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US7141597B2 (en) 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists
US20050059664A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Novel methods for identifying improved, non-sedating alpha-2 agonists
US20050058696A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
CA2553381C (en) 2004-01-20 2011-03-22 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US7691381B2 (en) 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244458A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20050244471A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
EP2216026B1 (en) 2004-07-12 2016-04-20 Allergan, Inc. Ophthalmic compositions and uses for treating ophthalmic conditions
US7675582B2 (en) * 2004-12-03 2010-03-09 Au Optronics Corporation Stacked storage capacitor structure for a thin film transistor liquid crystal display
US20060204548A1 (en) 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
US20060233857A1 (en) 2005-04-14 2006-10-19 Amsden Brian G Degradable elastomeric network
US20070260203A1 (en) 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US20070298073A1 (en) 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US9775932B2 (en) 2007-03-16 2017-10-03 The Regents Of The University Of California Nanostructure surface coated medical implants and methods of using the same
US7740604B2 (en) 2007-09-24 2010-06-22 Ivantis, Inc. Ocular implants for placement in schlemm's canal

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037056A2 (en) * 1998-12-23 2000-06-29 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
APEL A ET AL: "A subconjunctival degradable implant for cyclosporine delivery in corneal transplant therapy." CURRENT EYE RESEARCH. ENGLAND AUG 1995, vol. 14, no. 8, August 1995 (1995-08), pages 659-667, XP001083691 ISSN: 0271-3683 *
DAVIS, P. A. ET AL: "Intraocular implant for controlled 5-fluorouracil release" PROC. INT. SYMP. CONTROLLED RELEASE BIOACT. MATER., 19TH (1992), 339-40. EDITOR(S): KOPECEK, JINDRICH. PUBLISHER: CONTROLLED RELEASE SOC., DEERFIELD, ILL. , XP001084532 *
GOULD L ET AL: "Fifty:fifty poly (DL glycolic acid-lactic acid) copolymer as a drug delivery system for 5-fluorouracil: a histopathological evaluation." CANADIAN JOURNAL OF OPHTHALMOLOGY. JOURNAL CANADIEN D'OPHTALMOLOGIE. CANADA AUG 1994, vol. 29, no. 4, August 1994 (1994-08), pages 168-171, XP001083692 ISSN: 0008-4182 *
MORITA YASUSHI ET AL: "Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly(DL-lactic acid) implants." BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 21, no. 2, February 1998 (1998-02), pages 188-190, XP001084085 ISSN: 0918-6158 *
See also references of EP1339438A2 *
TAN DONALD T H ET AL: "Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation." OPHTHALMOLOGY, vol. 106, no. 2, February 1999 (1999-02), pages 223-231, XP001083687 ISSN: 0161-6420 *

Cited By (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9775849B2 (en) 2000-07-05 2017-10-03 Allergan, Inc. Implants and methods for treating inflammation-mediated conditions of the eye
US10206934B2 (en) 2000-07-05 2019-02-19 Allergan, Inc. Implants and methods for treating inflammation-mediated conditions of the eye
US10406029B2 (en) 2001-04-07 2019-09-10 Glaukos Corporation Ocular system with anchoring implant and therapeutic agent
EP1917957A3 (en) * 2003-01-09 2011-06-15 Allergan, Inc. Biodegradable ocular implant
EP3305284A1 (en) * 2003-01-09 2018-04-11 Allergan, Inc. Biodegradable ocular implant
EP3187177A1 (en) * 2003-01-09 2017-07-05 Allergan, Inc. Biodegradable ocular implant
US10076526B2 (en) 2003-01-09 2018-09-18 Allergan, Inc. Ocular implant made by a double extrusion process
EP3563839A1 (en) * 2003-01-09 2019-11-06 Allergan, Inc. Biodegradable ocular implant
US10702539B2 (en) 2003-01-09 2020-07-07 Allergan, Inc. Ocular implant made by a double extrusion process
US8048445B2 (en) 2003-01-09 2011-11-01 Allergan, Inc. Ocular implant made by a double extrusion process
JP2007526226A (en) * 2003-06-16 2007-09-13 ボシュ・アンド・ロム・インコーポレイテッド Rate-controlled release of pharmaceuticals in biodegradable devices
US9089478B2 (en) 2003-11-12 2015-07-28 Allergen, Inc. Peripherally administered viscous formulations
AU2005240081C1 (en) * 2004-04-30 2011-02-10 Allergan, Inc. Anti-excitotoxic sustained release intraocular implants and related methods
US10201641B2 (en) 2004-04-30 2019-02-12 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
EP1944032A3 (en) * 2004-04-30 2010-10-06 Allergan, Inc. Biodegradable intraocular implants containing prostamides
US10881608B2 (en) 2004-04-30 2021-01-05 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
WO2005110362A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Biodegradable ocular implants with long-term release characteristics
US9775846B2 (en) 2004-04-30 2017-10-03 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related implants
US10874605B2 (en) 2004-04-30 2020-12-29 Allergan, Inc. Extended release biodegradable ocular implants
WO2005110366A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. An estradiol derivative or an estratopone derivative containing sustained release intraocular implant as well as related methods of manufacturing
AU2005244195B2 (en) * 2004-04-30 2011-06-30 Allergan, Inc. Biodegradable ocular implants with long-term release characteristics
US9750751B2 (en) 2004-04-30 2017-09-05 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9707238B2 (en) 2004-04-30 2017-07-18 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US10864218B2 (en) 2004-04-30 2020-12-15 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US10064872B2 (en) 2004-04-30 2018-09-04 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US9669039B2 (en) 2004-04-30 2017-06-06 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US10076492B2 (en) 2004-04-30 2018-09-18 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
EP1740193A4 (en) * 2004-04-30 2012-10-24 Allergan Inc Macromolecule-containing sustained release intraocular implants and related methods
EP1740193A2 (en) * 2004-04-30 2007-01-10 Allergan, Inc. Macromolecule-containing sustained release intraocular implants and related methods
US10154960B2 (en) 2004-04-30 2018-12-18 Allergan, Inc. Extended release biodegradable ocular implants
US8529927B2 (en) 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
JP2007535540A (en) * 2004-04-30 2007-12-06 アラーガン、インコーポレイテッド Intravitreal implants combined with photodynamic therapy to improve vision
JP2007535566A (en) * 2004-04-30 2007-12-06 アラーガン、インコーポレイテッド Steroid intraocular implant that provides long-term sustained release for more than 2 months
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
AU2005240081B2 (en) * 2004-04-30 2010-06-24 Allergan, Inc. Anti-excitotoxic sustained release intraocular implants and related methods
US10406168B2 (en) 2004-04-30 2019-09-10 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
JP2014156496A (en) * 2004-04-30 2014-08-28 Allergan Inc Method for producing preparation of biodegradable microspheres
EP2777693A1 (en) * 2004-04-30 2014-09-17 Allergan, Inc. Biodegradable ocular implants with long-term release characteristics
WO2005107718A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Anti-excitotoxic sustained release intraocular implants and related methods
US8895049B2 (en) 2004-04-30 2014-11-25 Allergan, Inc. Extended release biodegradable ocular implants
US10398707B2 (en) 2004-04-30 2019-09-03 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related implants
US8911767B2 (en) 2004-04-30 2014-12-16 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8968766B2 (en) 2004-04-30 2015-03-03 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8974812B2 (en) 2004-04-30 2015-03-10 Allergan, Inc. Extended release biodegradable ocular implants
US9056045B2 (en) 2004-04-30 2015-06-16 Allergan, Inc. Intraocular biodegradable microspheres
JP2007535536A (en) * 2004-04-30 2007-12-06 アラーガン、インコーポレイテッド Polymer-containing sustained release intraocular implants and related methods
US10328086B2 (en) 2004-04-30 2019-06-25 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9233070B2 (en) 2004-04-30 2016-01-12 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
AU2010235967B2 (en) * 2004-08-13 2012-05-31 Allergan, Inc. Ocular implant made by a double extrusion process
AU2010235967C1 (en) * 2004-08-13 2013-01-17 Allergan, Inc. Ocular implant made by a double extrusion process
NO342740B1 (en) * 2004-08-13 2018-08-06 Allergan Inc Process for the preparation of a bioerodible implant, and bioerodible implant prepared thereby
AU2012216644B2 (en) * 2004-08-13 2014-04-10 Allergan, Inc. Ocular implant made by a double extrusion process
AU2018236685B2 (en) * 2004-08-13 2020-08-27 Allergan, Inc. Ocular implant made by a double extrusion process
CN102319432B (en) * 2004-08-13 2016-12-21 阿勒根公司 The ocular implant prepared by double squeeze
AU2016228285B2 (en) * 2004-08-13 2018-06-28 Allergan, Inc. Ocular implant made by a double extrusion process
WO2006036280A1 (en) * 2004-08-13 2006-04-06 Allergan, Inc. Ocular implant made by a double extrusion process
KR101451060B1 (en) * 2004-08-13 2014-10-14 알러간, 인코포레이티드 Ocular implant made by a double extrusion process
AU2014201844B2 (en) * 2004-08-13 2016-06-16 Allergan, Inc Ocular implant made by a double extrusion process
EP1870092A2 (en) 2004-08-13 2007-12-26 Allergan, Inc. Ocular implant made by a double extrusion process
EP2329811A1 (en) * 2004-08-13 2011-06-08 Allergan, Inc. Ocular implant obtained by multiple extrusion process
CN101083976B (en) * 2004-08-13 2011-08-31 阿勒根公司 Ocular implant made by a double extrusion process
EP1870092A3 (en) * 2004-08-13 2008-08-27 Allergan, Inc. Ocular implant
WO2007109530A1 (en) * 2006-03-20 2007-09-27 Allergan, Inc. Cyclosporin a compositions
US10669383B2 (en) 2006-10-31 2020-06-02 Evonik Corporation Spheronized polymer particles
WO2008093086A1 (en) 2007-01-31 2008-08-07 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses
US9434758B2 (en) 2008-05-28 2016-09-06 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
EP2444092A1 (en) * 2008-05-28 2012-04-25 Validus Biopharma, Inc. Non-hormonal steroid modulators of nf-kb for treatment of disease
EP2278978A2 (en) * 2008-05-28 2011-02-02 Validus Biopharma, Inc. Non-hormonal steroid modulators of nf-kb for treatment of disease
CN103739647B (en) * 2008-05-28 2017-06-09 雷沃根生物医药有限公司 Non- steroid conditioning agent for treating the NF κ B of disease
US9649320B2 (en) 2008-05-28 2017-05-16 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
EP2278978A4 (en) * 2008-05-28 2011-06-15 Validus Biopharma Inc Non-hormonal steroid modulators of nf-kb for treatment of disease
US11833159B2 (en) 2008-05-28 2023-12-05 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kB for treatment of disease
US10857161B2 (en) 2008-05-28 2020-12-08 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kB for treatment of disease
US10206933B2 (en) 2008-05-28 2019-02-19 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kB for treatment of disease
US8207151B2 (en) 2008-05-28 2012-06-26 Validus Biopharma Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
US8334279B2 (en) 2008-05-28 2012-12-18 Validus Genetics Non-hormonal steroid modulators of NF-κB for treatment of disease
US8673887B2 (en) 2008-05-28 2014-03-18 Reveragen Biopharma, Inc Non-hormonal steroid modulators of NF-kB for treatment of disease
CN103739647A (en) * 2008-05-28 2014-04-23 雷沃根生物医药有限公司 Non-hormonal steroid modulators of nf-kb for treatment of disease
AU2009260471B2 (en) * 2008-05-28 2014-12-11 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-KB for treatment of disease
US11426306B2 (en) 2009-05-18 2022-08-30 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US10278919B2 (en) 2010-01-22 2019-05-07 Allergan, Inc. Intracameral sustained release therapeutic agent implants
US8647659B2 (en) 2010-01-22 2014-02-11 Allergan, Inc. Intracameral sustained release therapeutic agent implants
US9504696B2 (en) 2010-01-22 2016-11-29 Allergan, Inc. Intracameral sustained release therapeutic agent implants
US9198921B2 (en) 2010-04-05 2015-12-01 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
US10000525B2 (en) 2010-04-05 2018-06-19 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
WO2012003210A1 (en) * 2010-06-30 2012-01-05 Surmodics Pharmaceuticals, Inc. Implant processing methods for thermally labile and other bioactive agents and implants prepared from same
US10231926B2 (en) 2013-02-15 2019-03-19 Allergan, Inc. Sustained drug delivery implant
US9610246B2 (en) 2013-02-15 2017-04-04 Allergan, Inc. Sustained drug delivery implant
US11253394B2 (en) 2013-03-15 2022-02-22 Dose Medical Corporation Controlled drug delivery ocular implants and methods of using same
US9980974B2 (en) 2013-10-31 2018-05-29 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
US10959941B2 (en) 2014-05-29 2021-03-30 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
WO2016079204A1 (en) 2014-11-18 2016-05-26 Pierre Coulon Multifunctional capsular implant
AU2016269848B2 (en) * 2015-06-02 2021-12-09 Intravital Pty Ltd Formulation and process for limiting nerve trauma
US11324758B2 (en) 2015-06-02 2022-05-10 Intravital Pty Ltd Formulation and process for limiting nerve trauma
WO2016191820A1 (en) * 2015-06-02 2016-12-08 Newsouth Innovations Pty Limited Formulation and process for limiting nerve trauma
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US11318043B2 (en) 2016-04-20 2022-05-03 Dose Medical Corporation Bioresorbable ocular drug delivery device
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
US11471471B2 (en) 2019-03-07 2022-10-18 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Also Published As

Publication number Publication date
US20070190112A1 (en) 2007-08-16
DK1339438T3 (en) 2006-02-13
US20070298076A1 (en) 2007-12-27
AU2006201271A1 (en) 2006-04-27
AU2002236495B2 (en) 2006-05-11
DE60114229T2 (en) 2006-07-06
US20150005272A1 (en) 2015-01-01
US20060198871A1 (en) 2006-09-07
DE60114229D1 (en) 2006-03-02
US20120059462A1 (en) 2012-03-08
JP2004210798A (en) 2004-07-29
US7846468B2 (en) 2010-12-07
JP2006193532A (en) 2006-07-27
US9592242B2 (en) 2017-03-14
US8828446B2 (en) 2014-09-09
US20160193230A1 (en) 2016-07-07
US7767223B2 (en) 2010-08-03
CA2429998A1 (en) 2002-06-06
US20020182185A1 (en) 2002-12-05
BR0115772A (en) 2004-01-13
US8043628B2 (en) 2011-10-25
EP1339438A2 (en) 2003-09-03
CA2429998C (en) 2012-01-17
US20080069859A1 (en) 2008-03-20
US20090062249A1 (en) 2009-03-05
JP2004514702A (en) 2004-05-20
US20120022034A1 (en) 2012-01-26
US8088407B2 (en) 2012-01-03
US20130274689A1 (en) 2013-10-17
US8071120B2 (en) 2011-12-06
ES2250504T3 (en) 2006-04-16
US20080050420A1 (en) 2008-02-28
US20080050421A1 (en) 2008-02-28
EP1339438B1 (en) 2005-10-19
US6699493B2 (en) 2004-03-02
US9283178B2 (en) 2016-03-15
WO2002043785A3 (en) 2002-11-21
AU3649502A (en) 2002-06-11
AU2006201271B2 (en) 2006-08-24
ATE306951T1 (en) 2005-11-15
US20050249710A1 (en) 2005-11-10
US7625582B2 (en) 2009-12-01
US7033605B2 (en) 2006-04-25
US20170182064A1 (en) 2017-06-29
US20040137034A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
US9592242B2 (en) Methods for treating edema in the eye and intraocular implants for use therefor
US20200261271A1 (en) Intraocular drug delivery
AU2002236495A1 (en) Intraocular implants for preventing transplant rejection in the eye
US6726918B1 (en) Methods for treating inflammation-mediated conditions of the eye
AU2001273166A1 (en) Methods for treating inflammation-mediated conditions of the eye
EP1550471A1 (en) Intraocular implants for preventing transplant rejection in the eye

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002236495

Country of ref document: AU

Ref document number: 2429998

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002545755

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001986027

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001986027

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001986027

Country of ref document: EP